View Filing Data

Print Document View Excel Document

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2019	Mar. 26, 2020	Jun. 28, 2019
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Trading Symbol	ALT
Entity Registrant Name	ALTIMMUNE, INC.
Entity Central Index Key	0001326190
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		15,361,660
Entity Public Float			$ 28,792,136
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common stock, par value $0.0001 per share
Security Exchange Name	NASDAQ
Entity File Number	001-32587
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-2726770
Entity Address, Address Line One	910 Clopper Road
Entity Address, Address Line Two	Suite 201S
Entity Address, City or Town	Gaithersburg
Entity Address, State or Province	MD
Entity Address, Postal Zip Code	20878
City Area Code	(240)
Local Phone Number	654-1450
Document Annual Report	true
Document Transition Report	false

Consolidated Balance Sheets - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 8,962,686	$ 33,718,713
Restricted cash	34,174	634,416
Total cash, cash equivalents, and restricted cash	8,996,860	34,353,129
Short-term investments	28,277,386
Accounts receivable	1,021,179	3,461,938
Tax refund receivable	629,096	1,008,973
Prepaid expenses and other current assets	470,228	548,094
Total current assets	39,394,749	39,372,134
Property and equipment, net	1,104,208	1,342,802
Right of use asset	698,321
Intangible assets, net	12,732,195	13,851,924
Other assets	128,547	183,682
Total assets	54,058,020	54,750,542
Current liabilities:
Notes payable		71,596
Accounts payable	18,232	372,860
Accrued expenses and other current liabilities	3,904,767	4,082,949
Total current liabilities	3,922,999	4,527,405
Deferred income taxes		58,500
Contingent consideration	2,750,000
Other long-term liabilities	1,864,875	1,852,071
Total liabilities	8,537,874	6,437,976
Commitments and contingencies (Note 16)
Stockholders’ equity:
Common stock, $0.0001 par value; 200,000,000 shares authorized; 15,312,381 and 9,078,735 shares issued; 15,312,167 and 9,078,238 shares outstanding at December 31, 2019 and 2018, respectively	1,508	876
Additional paid-in capital	187,914,916	170,207,844
Accumulated deficit	(137,376,122)	(116,855,991)
Accumulated other comprehensive loss, net	(5,020,156)	(5,040,163)
Total stockholders’ equity	45,520,146	48,312,566
Total liabilities and stockholders’ equity	$ 54,058,020	$ 54,750,542

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2019	Dec. 31, 2018
Statement Of Financial Position [Abstract]
Common stock, par or stated value per share	$ 0.0001	$ 0.0001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	15,312,381	9,078,735
Common stock, shares outstanding	15,312,167	9,078,238

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Statement [Abstract]
Revenue	$ 5,801,401	$ 10,331,168
Operating expenses
Research and development	17,765,553	18,459,310
General and administrative	8,500,783	9,765,581
Impairment charges	1,000,000	24,940,687
Total operating expenses	27,266,336	53,165,578
Loss from operations	(21,464,935)	(42,834,410)
Other income (expense)
Changes in fair value of warrant liability, including loss on exchange	30,000	(2,878,484)
Changes in fair value of embedded derivative		184,555
Interest expense	(2,244)	(297,090)
Interest income	843,409	226,597
Other income, net	15,139	277,886
Total other income (expense)	886,304	(2,486,536)
Net loss before income tax benefit	(20,578,631)	(45,320,946)
Income tax benefit	58,500	6,149,794
Net loss	(20,520,131)	(39,171,152)
Other comprehensive loss — foreign currency translation adjustment		(463,177)
Other comprehensive income — unrealized gains on investments	20,007
Comprehensive loss	(20,500,124)	(39,634,329)
Net loss	(20,520,131)	(39,171,152)
Preferred stock accretion and other deemed dividends	(452,925)	(3,307,800)
Net loss attributable to common stockholders	$ (20,973,056)	$ (42,478,952)
Weighted-average common shares outstanding, basic and diluted	13,124,951	2,802,382
Net loss per share attributable to common stockholders, basic and diluted	$ (1.60)	$ (15.16)

Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity - USD ($)	Total	Public Offering [Member]	Series B Redeemable Convertible Preferred Stock [Member]	Common Stock [Member]	Common Stock [Member] Public Offering [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member] Public Offering [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]
Beginning Balance at Dec. 31, 2017	$ 39,395,823			$ 61		$ 121,657,587		$ (77,684,839)	$ (4,576,986)
Beginning Balance (in shares) at Dec. 31, 2017			12,177
Beginning Balance at Dec. 31, 2017			$ 9,281,767
Beginning Balance (in shares) at Dec. 31, 2017				608,499
Stock based compensation	762,162					762,162
Vesting and accelerated vesting of restricted stock, net	11,203					11,203
Vesting and accelerated vesting of restricted stock, net (in shares)				284
Exercises of stock options	22,898			$ 1		22,897
Exercises of stock options (in shares)				9,540
Accretion of Series B redeemable convertible preferred stock	(2,894,885)					(2,894,885)
Accretion of Series B redeemable convertible preferred stock			$ 2,894,885
Conversion of Series B redeemable convertible preferred stock into common stock	9,790,367			$ 50		9,790,317
Conversion of Series B redeemable convertible preferred stock into common stock (in shares)			(9,813)
Conversion of Series B redeemable convertible preferred stock into common stock			$ (9,790,367)
Conversion of Series B redeemable convertible preferred stock into common stock (in shares)				502,078
Redemption of Series B redeemable convertible preferred stock for cash and release of embedded derivative	23,292					23,292
Redemption of Series B redeemable convertible preferred stock for cash and release of embedded derivative (in shares)			(2,364)
Redemption of Series B redeemable convertible preferred stock for cash and release of embedded derivative			$ (2,386,285)
Issuance of common stock for the exchange of warrants	3,433,041			$ 32		3,433,009
Issuance of common stock for the exchange of warrants (in shares)				318,668
Issuance of common stock and units, net of offerings cost	26,735,488	$ 10,667,506		$ 491	$ 241	26,734,997	$ 10,667,265
Issuance of common stock and units, net of offering costs (in shares)				4,916,263	2,400,000
Foreign currency translation adjustments	(463,177)								(463,177)
Net loss	(39,171,152)							(39,171,152)
Ending Balance at Dec. 31, 2018	48,312,566			$ 876		170,207,844		(116,855,991)	(5,040,163)
Ending Balance (in shares) at Dec. 31, 2018				9,078,238
Stock based compensation	1,264,231					1,264,231
Vesting and accelerated vesting of restricted stock, net	(47,120)			$ 6		(47,126)
Vesting and accelerated vesting of restricted stock, net (in shares)				(25,691)
Issuance of common stock upon exercise of warrants	30,324			$ 1		30,323
Issuance of common stock upon exercise of warrants (in shares)				11,000
Issuance of common stock and units, net of offerings cost	12,668,784			$ 436		12,668,348
Issuance of common stock and units, net of offering costs (in shares)				4,361,370
Issuance of common stock for acquired in-process research and development	3,791,485			$ 189		3,791,296
Issuance of common stock for acquired in-process research and development (in shares)				1,887,250
Unrealized gain on short term investments	20,007								20,007
Net loss	(20,520,131)							(20,520,131)
Ending Balance at Dec. 31, 2019	$ 45,520,146			$ 1,508		$ 187,914,916		$ (137,376,122)	$ (5,020,156)
Ending Balance (in shares) at Dec. 31, 2019				15,312,167

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Dec. 31, 2019	Dec. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (20,520,131)	$ (39,171,152)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash consideration for acquired in-process research and development	6,541,485
Impairment charges	1,000,000	24,940,687
Stock-based compensation	1,264,231	773,248
Depreciation	239,821	218,717
Amortization	147,500	83,652
Unrealized (gain) loss on foreign currency exchange	(5,761)	64,806
Debt discount accretion		180,611
Gain from disposal of property and equipment		(3,806)
Changes in fair value of warrant liability	(30,000)	2,878,484
Changes in fair value of embedded derivative		(184,555)
Changes in operating assets and liabilities:
Accounts receivable	2,440,759	344,301
Prepaid expenses and other current assets	133,001	499,391
Accounts payable	(354,628)	243,062
Accrued expenses and other current liabilities	(626,193)	17,110
Deferred revenue	22,032	(19,780)
Deferred rent		818,893
Lease obligation	(175,490)
Tax refund receivable	379,877	5,077,217
Deferred tax benefit	(58,500)	(6,149,794)
Net cash used in operating activities	(9,601,997)	(9,388,908)
CASH FLOWS FROM INVESTING ACTIVITIES
Cash paid for short-term investments	(28,257,379)
Purchases of property and equipment	(1,227)	(975,407)
Proceeds from sale of property and equipment		14,492
Additions to intangible assets	(27,772)	(40,227)
Net cash used in investing activities	(28,286,378)	(1,001,142)
CASH FLOWS FROM FINANCING ACTIVITIES
Repayments of notes payable	(292,002)	(1,549,702)
Redemption of preferred stock		(2,386,285)
Cash paid in conjunction with warrant exchange	(25,000)	(1,100,000)
Proceeds from conditional economic incentive	150,000	100,000
Proceeds from issuance of common stock, net of issuance costs		4,334,816
Proceeds from issuance of common units, net of issuance costs	12,668,784	33,068,178
Proceeds from exercise of warrants and stock options	30,324	22,898
Net cash provided by financing activities	12,532,106	32,489,905
EFFECT OF EXCHANGE RATES ON CASH, CASH EQUIVALENTS, AND RESTRICTED CASH		(50,365)
Net (decrease) increase in cash, cash equivalents, and restricted cash	(25,356,269)	22,049,490
Cash, cash equivalents, and restricted cash — beginning of year	34,353,129	12,303,639
Cash, cash equivalents, and restricted cash — end of year	8,996,860	34,353,129
SUPPLEMENTAL CASH FLOW INFORMATION
Cash paid for interest		57,214
SUPPLEMENTAL NON-CASH FINANCING ACTIVITIES
Common Stock issued for acquired in-process research and development	$ 3,791,485
Settlement of warrant liability for common stock		3,345,030
Notes payable issued in conjunction with the exchange of warrants		1,500,000
Series B Redeemable Convertible Preferred Stock [Member]
SUPPLEMENTAL NON-CASH FINANCING ACTIVITIES
Conversion of Series B redeemable convertible preferred stock into common stock		9,790,367
Accretion of Series B redeemable convertible preferred stock		$ 2,894,885

Nature of Business and Basis of Presentation

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Nature of Business and Basis of Presentation

1.	Nature of Business and Basis of Presentation

Nature of Business

Altimmune, Inc., headquartered in Gaithersburg, Maryland, United States, together with its subsidiaries (collectively, the “Company” or “Altimmune”) is a clinical stage biopharmaceutical company incorporated under the laws of the State of Delaware.

The Company’s business is a result of a merger between PharmAthene, Inc. (“PharmAthene”) and the business previously known as Altimmune, Inc. (“Private Altimmune”). In May of 2017, Private Altimmune merged with PharmAthene pursuant to an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) dated January 18, 2017. Except where the context indicates otherwise, references to “we,” “us,” “our,” “Altimmune” or the “Company” refer, for periods prior to the completion of the Mergers, to Private Altimmune and its subsidiaries, and for periods following the completion of the Mergers to the combined company and its subsidiaries.

The Company is focused on developing treatments for liver disease and immune modulating therapies. Our diverse pipeline includes next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™), conjugated immunostimulants for the treatment of cancer (ALT-702) and intranasal vaccines (NasoVAX™ and NasoShield™). The Company has not generated any revenues from the sale of any products to date, and there is no assurance of any future revenues from product sales.

Basis of Presentation

The accompanying consolidated financial statements are prepared in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”) and in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”).

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2.	Summary of Significant Accounting Policies

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries, all of which are wholly owned. Intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates relied upon in preparing the accompanying consolidated financial statements were related to revenue recognition, the fair value of common stock and other equity instruments, accounting for stock-based compensation, income taxes, collectability of accounts receivable, useful lives of long-lived assets, fair value of contingent consideration acquired, impairment of goodwill and other long-lived assets, and accounting for project development and certain accruals. The Company assesses the above estimates on an ongoing basis; however, actual results could differ materially from those estimates.

Comprehensive Loss

For the years presented, the total comprehensive loss includes net loss and other comprehensive loss which represents unrealized gains on investments and foreign currency translation adjustments.

Foreign Currency Translation

Historically the Company’s UK subsidiaries utilized the British pound as their functional currency. The assets and liabilities of these subsidiaries were translated at current exchange rates, while revenue and expenses were translated at the average rates in effect for the period. The related translation gains and losses were included in other comprehensive income or loss within the Consolidated Statements of Operations and Comprehensive Loss. As a result of an analysis which took into account the economic indicators of these subsidiaries from a long-term perspective, the Company changed the functional currency for these subsidiaries from British Pounds to U.S. Dollars effective as of July 1, 2018. The change in the Company’s functional currency determination has been applied on a prospective basis in accordance with ASC 830. Therefore, any translation gains and losses that were previously recorded in accumulated other comprehensive income through June 30, 2018 remain unchanged as of December 31, 2019.

Segment

The Company is managed and operates as a single business focused on the research and development of immunotherapies and vaccines. The Company is managed by a single management team, and, consistent with its organizational structure, the Chief Executive Officer manages and allocates resources at a consolidated level. Accordingly, the Company views its business as one reportable operating segment.

Investments

The Company’s short-term investments are comprised of U.S. Treasury and corporate debt securities that have original maturities less than or equal to one year and are classified as available-for-sale securities. Such securities are carried at estimated fair value, with any unrealized holding gains or losses reported as accumulated other comprehensive income or loss, which is a separate component of stockholders’ equity. Realized gains and losses and declines in value judged to be other-than-temporary, if any, are included in other income in the consolidated results of operations. The Company reviews its investment portfolio for impairment quarterly or more frequently if circumstances warrant. In determining whether a decline in the value of an investment is other-than-temporary, the Company evaluates currently available factors that may include, among others: (1) general market conditions; (2) the duration and extent to which fair value has been less than the carrying value; (3) the investment issuer's financial condition and business outlook; and (4) its assessment as to whether it is more likely than not that the Company will be required to sell a security prior to recovery of its amortized cost basis. A decline in the market value of any available-for-sale security below cost that is deemed to be other-than-temporary results in a reduction in fair value charged to earnings in that period, and a new cost basis for the security is established. Dividend and interest income are recognized in other income when earned. The cost of securities sold is calculated using the specific identification method. The Company places all investments with government agencies, or corporate institutions whose debt is rated as investment grade. Investments are classified as either current or non-current assets on our consolidated balance sheets based on their contractual maturity dates.

Intangible Assets

Intangible assets acquired in a business combination consist primarily of in-process research and development (“IPR&D”) assets. The value attributable to IPR&D projects at the time of acquisition is capitalized as an indefinite-lived intangible asset and tested for impairment until the project is completed or abandoned. Upon completion of the project, the indefinite-lived intangible asset will be accounted for as a finite-lived intangible asset and amortized on a straight-line basis over its estimated useful life. If the project is abandoned, the indefinite-lived intangible asset will be charged to expense. Intangible assets, including patents and licenses, acquired in other transactions are recorded at cost. Intangible assets with finite useful lives consist of legal costs incurred in the course of obtaining patents and license issuance fees for the use of proprietary technologies. Costs incurred for obtaining patents are amortized on a straight-line basis over the estimated useful lives of the assets from the time of approval of the patent. Prior to approval, these costs are carried on the balance sheets and not amortized. In the event approval is denied, the cost of the denied application is expensed. License issuance fees are amortized on a straight-line basis over the estimated useful lives of the underlying licensed technology. Intangible assets with finite useful lives are being amortized over 6 to 20 years and are evaluated separately from indefinite-lived intangible assets for impairment at least annually or whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. These amortization costs are classified as research and development expenses in the accompanying statements of operations and comprehensive loss.

Impairment of Long-lived Assets and Goodwill

The Company evaluates our long-lived tangible and intangible assets, including IPR&D assets and goodwill, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Impairment of long-lived assets other than goodwill and indefinite lived intangibles is assessed by comparing the undiscounted cash flows expected to be generated by the asset to its carrying value. Prior to the complete impairment of goodwill in 2018, goodwill was tested for impairment by comparing the estimated fair value of our single reporting unit to its carrying value.

The Company’s IPR&D assets are currently non-amortizing. Until such time as the projects are either completed or abandoned, the Company test those assets for impairment at least annually at year end, or more frequently at interim periods, by evaluating qualitative factors which could be indicative of impairment. Qualitative factors being considered include, but are not limited to, the current project status, forecasted changes in the timing or amounts required to complete the project, forecasted in timing or changes in the future cash flows to be generated by the completed products, and changes to other market-based assumptions, such as discount rates. If impairment indicators are present as a result of our qualitative assessment, the Company will test those assets for impairment by comparing the fair value of the assets to their carrying value. Upon completion or abandonment, the value of the IPR&D assets will be amortized to expense over the anticipated useful life of the developed products, if completed, or charged to expense when abandoned if no alternative future use exists.

During the fourth quarter of 2018, the Company recorded $24,450,011 of impairments related to IPR&D assets. During 2019, the Company recorded $1,000,000 of impairments related to IPR&D assets. See Note 6 for further details.

During the year ended December 31, 2018, the goodwill impairment charges of $490,676 represented an adjustment recorded to reduce the tax refund receivable acquired in connection with a 2017 business combination. There was no goodwill balance outstanding as of December 31, 2019 and 2018.

Fair Value Measurements

The Company records certain financial assets and liabilities at fair value in accordance with the guidance in Financial Accounting Standards Board (“FASB”) Accounting Standard Codification (“ASC”) 820, Fair Value Measurements and Disclosures, which defines fair value and establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described below:

Level 1 — Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can access at the measurement date.

Level 2 — Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable. If the asset or liability has a specified (contractual) term, a Level 2 input must be observable for substantially the full term.

Level 3 — Unobservable inputs developed using estimates of assumptions developed by the Company, which reflect those that a market participant would use.

To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

Fair value is a market-based measure considered from the perspective of a market participant rather than an entity-specific measure. Therefore, even when market assumptions are not readily available, the Company’s own assumptions are set to reflect those that market participants would use in pricing the asset or liability at the measurement date. The Company uses prices and inputs that are current as of the measurement date, including during periods of market dislocation. In periods of market dislocation, the observability of prices and inputs may change for many instruments. This condition could cause an instrument to be reclassified within levels in the fair value hierarchy. There were no transfers within the fair value hierarchy during the years ended December 31, 2019 and 2018.

Financial Instruments

The Company’s financial instruments consist of cash, cash equivalents, restricted cash, accounts receivable, short-term investments, notes payable, accounts payable, accrued expenses, BPI France notes, contingent consideration, common stock warrants classified as a liability, common stock warrants classified as equity, convertible preferred stock, redeemable convertible preferred stock, and an embedded derivative. The carrying amounts of cash, cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued expenses approximate their fair value due to the short-term nature of those financial instruments. Short-term investments are recorded at fair value, with any unrealized holding gains or losses reported as accumulated other comprehensive income or loss. The BPI France notes prior to their redemption or cancellation are recorded at their repayment value which approximates fair value. Contingent payments classified as a liability was recorded at fair value estimated using the Monte Carlo simulation valuation model. Redeemable convertible preferred stock until its redemption was classified as temporary equity and its carrying amount accreted over the term of the instrument up to its liquidation and redemption value. Common stock warrants classified as equity and convertible preferred stock classified as temporary equity are initially recorded at their grant date fair value. For those warrants with a down round feature, if the down round feature is triggered the Company would remeasure those instruments at that time with changes recorded as a deemed dividend all within equity. Common stock warrants classified as a liability and the embedded derivative are recorded at fair value and are remeasured every reporting period with the changes in fair value recorded as a component of other income (expenses), net until their settlement or exercise.

Revenue

Our revenue consists primarily of government and foundation grants and contracts that support the Company’s efforts on specific research projects. The Company has determined that the government agencies and foundations providing grants and contracts to the Company are not customers. These grants and contracts generally provide for reimbursement of approved costs as those costs are incurred by the Company. Research grants and contracts and the related accounts receivable are recognized as earned when reimbursable expenses are incurred and the performance obligation is complete. Payments received in advance of services being provided are recorded as deferred revenue.

Research and Development

Research and development costs are expensed as incurred. Research and development costs include payroll and personnel expense, consulting costs, external contract research and development expenses, raw materials, drug product manufacturing costs, and allocated overhead, including depreciation and amortization, rent and utilities. Research and development costs that are paid in advance of performance are capitalized as a prepaid expense and amortized over the service period as the services are provided.

Clinical Trial Costs

Clinical trial costs are a component of research and development expenses. The Company accrues and expenses clinical trial activities performed by third parties based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activation, and other information provided to the Company by our vendors.

Cash Equivalents

The Company considers all highly liquid investments purchased with remaining maturities of 90 days or less on the purchase date to be cash equivalents, and include amounts held in money market funds which are actively traded (a Level 1 input).

Restricted Cash

The Company had restricted cash of $34,174 and $634,416 at December 31, 2019 and 2018, respectively held in money market savings accounts as collateral. The restricted cash as of December 31, 2019 is for the Company’s facility lease obligation. The restricted cash as of December 31, 2018, was for the Company’s facility lease obligation and $600,000 for a legal bond supporting the Company’s attempt to collect on amounts previously due from a third-party that was released from restriction in 2019. Restricted cash is classified as a component of cash, cash equivalents, and restricted cash in the accompanying consolidated balance sheets and consolidated statements of cash flows.

Accounts Receivable

Accounts receivable includes both billed and unbilled amounts. The Company makes judgments as to its ability to collect outstanding receivables and provides an allowance for receivables when collection becomes doubtful. Provisions are made based upon a specific review of all significant outstanding invoices and the overall quality and age of those invoices not specifically reviewed. The Company’s receivables represent amounts reimbursed under its government grants and contracts. The Company believes that credit risks associated with these government grants and contracts is not significant. To date, the Company has not experienced any losses associated with accounts receivable and does not maintain an allowance for doubtful accounts.

Concentrations of Credit Risk

Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents, restricted cash, and accounts receivable. Periodically, the Company maintains deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company’s deposits are held at financial institutions that management believes to be of high credit quality. The Company has not experienced any losses in these deposits. The Company recognizes research grants and contracts earned in connection with the services provided on research and development projects. The Company provides credit in the normal course of providing such services based on evaluations of the grantors’ financial condition and generally does not require collateral. To manage accounts receivable credit risk, the Company monitors the creditworthiness of its grantors. The U.S. Government accounts for 100% of research grants and contracts and accounts receivable for the years ended December 31, 2019 and 2018. As discussed above, the Company believes that credit risks associated with these government grants and contracts and accounts receivable is not significant.

Property and Equipment, Net

The Company records property and equipment at cost less accumulated depreciation and amortization. Expenditures for maintenance and repairs are charged to operations as incurred, whereas major improvements are capitalized as additions to property and equipment. Costs of assets under construction are capitalized but are not depreciated until the construction is substantially complete and the assets being constructed are ready for their intended use.

Depreciation and amortization are recorded using the straight-line method over the estimated useful lives of the assets, as follows:

Asset Category		Estimated Useful Life
Computer and telecommunications		3 – 5 years
Software		3 years
Furniture, fixtures and equipment		5 years
Laboratory equipment		7 years
Leasehold improvements		Lesser of lease term or estimated useful lives

Preferred Stock

Shares of redeemable preferred stock were issued in August 2017. Redeemable preferred stock was classified as temporary equity and was initially recorded at its original issuance price, net of issuance costs and discounts. Such discounts included common stock warrants issued as part of the financing which were required to be classified as a liability and recorded at fair value (Note 12), an embedded derivative related to certain redemption features which was classified as a liability and recorded at fair value (Note 10), and the intrinsic value of a beneficial conversion feature present in the instrument at issuance (Note 10). The carrying value of the redeemable preferred stock was accreted over the term of the redeemable preferred stock up to its redemption value, using the straight-line method which approximates the effective interest method due to the short-term nature of the redeemable preferred stock terms with the amount of the accretion recorded as a reduction of additional paid-in capital. All redeemable preferred stock was either redeemed or converted during the year ended December 31, 2018.

Warrants

Common stock warrants issued in connection with the redeemable preferred stock in 2017 were classified as a liability because these warrants contained terms which could, in certain circumstances, required the Company to settle the instruments for cash and such circumstances are outside the Company’s control. Common stock warrants classified as a liability are initially recorded at their issuance date fair value and are remeasured on each subsequent balance sheet date with changes in fair value recorded as a component of other income (expenses), net. These common stock warrants were valued using the Monte Carlo simulation valuation model. These warrants were subsequently redeemed in 2018 (Note 12).

Common stock warrants issued in connection with the Unit Offering (as defined in Note 11), the Second Registered Direct Offering (as defined in Note 11), and the Third Registered Direct Offering (as defined in Note 11) were classified as a component of permanent equity because they are freestanding financial instruments that were legally detachable and separately exercisable from other debt and equity instruments, are contingently exercisable, do not embody an obligation for the Company to repurchase its shares, and permits the holders to receive a fixed number of common shares upon exercise. In addition, such warrants did not provide any guarantee of value or return. The Second Registered Direct Offering and Third Registered Direct Offering triggered down round adjustments to the exercise price of warrants issued in connection with the unit offering. The Company treated the value of the effect of the reduction in exercise price as a deemed dividend, resulting in a reduction to income available to common shareholders (Note 12).

Stock-based Compensation

The Company accounts for all stock-based compensation granted to employees and non-employees using a fair value method. Stock-based compensation awarded to employees is measured at the grant date fair value of stock option grants and is recognized over the requisite service period of the awards, usually the vesting period, on a straight-line basis, net of estimated forfeitures. For performance-based awards where the vesting of the options may be accelerated upon the achievement of certain milestones, vesting and the related stock-based compensation is recognized as an expense when it is probable the milestone will be met. For awards containing a market condition, the effect of the market condition is reflected in measuring the grant date fair value of the award and is recognized over the requisite service period, which is usually the vesting period, on a straight-line basis, net of estimated forfeitures.

When awards are modified, the Company compares the fair value of the affected award measured immediately prior to modification to its value after modification. To the extent that the fair value of the modified award exceeds the original award, the incremental fair value of the modified award is recognized as compensation on the date of modification for vested awards, and over the remaining vesting period for unvested awards.

Income Taxes

The Company accounts for income taxes using the asset and liability approach, which requires the recognition of future tax benefits or liabilities on the temporary differences between the financial reporting and tax bases of our assets and liabilities. Deferred tax assets and liabilities represent future tax consequences of temporary differences between the financial statement carrying amounts and the tax basis of assets and liabilities and for loss carryforwards using enacted tax rates expected to be in effect in the years in which the differences reverse. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company also recognizes a tax benefit from uncertain tax positions only if it is “more likely than not” that the position is sustainable based on its technical merits. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes. To date, the Company has not incurred interest and penalties related to uncertain tax positions. Should such costs be incurred, they would be classified as a component of provision for income taxes.

Net Loss per Share

Basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period without consideration for potentially dilutive securities. Net loss attributable to common stockholders and participating preferred stock is allocated to each share on an as-converted basis as if all of the net loss for the period had been distributed. During periods in which the Company incurred a net loss, the Company does not allocate net loss to participating securities because they do not have a contractual obligation to share in the net loss of the Company.

The Company computes diluted net loss per common share after giving consideration to all potentially dilutive common equivalents, including convertible preferred stock, redeemable preferred stock, common stock options, restricted stock awards, and common stock warrants outstanding during the period except where the effect of such non-participating securities would be antidilutive.

Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods.

Leases

The Company’s headquarters lease is the primary lease, accounted for as an operating lease under the new lease accounting guidance, which the Company adopted on January 1, 2019 under the prospective optional transition method.

The Company determines if an arrangement is a lease at inception. Operating leases are recorded as a current and long-term lease obligation, with a corresponding right of use lease assets.

The lease obligations represent the Company’s obligation to make lease payments arising from the lease. The right of use lease assets represent the Company’s right to use an underlying asset for the lease term. The lease obligations and the operating right of use lease assets are recognized at the commencement date based on the present value of lease payments over the lease term. As most of the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

Short-term leases are leases having a term of twelve months or less. The Company recognizes short-term leases on a straight-line basis and does not record a related lease asset or liability for such leases.

Lease incentives and allowance provided by our landlord for the construction of leasehold improvements are recorded as lease incentive obligations as the related construction costs are incurred, up to the maximum allowance.

Contingent Consideration

The Company records contingent consideration associated with development and regulatory milestones that meets the definition of a liability under ASC 480 at fair value. The fair value model used to calculate this obligation is based on the income approach (a discounted cash flow model) or a Monte Carlo simulation, if more appropriate, that has been risk adjusted based on the probability of achievement of the milestones. The inputs the Company uses for determining the fair value of the contingent consideration associated with development and regulatory milestones are Level 3 fair value measurements. The Company re-evaluates the fair value on a quarterly basis. Changes in the fair value can result from adjustments to the discount rates and updates in the assumed timing of milestone achievement. Any future increase in the fair value of the contingent consideration associated with development and regulatory milestones are based on an increased likelihood that the underlying milestones will be achieved.

The change in Company’s estimates associated with payments which will become due and payable for development and regulatory milestones will change the fair value of contingent consideration, resulting in a charge or contra expense to research and development expense in the period in which the increase or decrease is determined.

Recently Issued Accounting Pronouncements

Recently Adopted:

In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (“ASU 2016-02”). ASU 2016-02 requires a lessee to separate the lease components from the non-lease components in a contract and recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018. The standard requires a modified retrospective approach or an optional transition to apply the new guidance in the year of transition rather than at the beginning of the earliest period presented. The Company adopted ASU 2016-02 in the first quarter of 2019 under the optional transition method. The Company’s existing operating leases were accounted for as operating lease liabilities and right of use assets upon adoption. The Company has elected the package of practical expedients permitted. Accordingly, the Company accounted for its existing operating leases as operating leases under the new guidance, without reassessing (a) whether the contracts contain a lease, (b) whether classification of the operating leases would be different in accordance, or (c) whether the unamortized initial direct costs before transition adjustments would have met the definition of initial direct costs at lease commencement. In addition, the Company does not allocate the consideration between lease and non-lease components. The adjustment resulted in an increase of $756,347 to total assets and total liabilities on the January 1, 2019 consolidated balance sheet. The adoption did not have a material impact on the consolidated statement of operations or consolidated statement of cash flows.

In June 2018, FASB issued ASU No. 2018-07, Compensation—Stock Compensation (Topic 718)—Improvements to Nonemployee Share-Based Payment Accounting (“ASU 2018-07”). ASU 2018-07 expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The Company adopted ASU 2018-07 in the first quarter of 2019. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements.

Pending Adoptions:

In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which required entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. This update also required enhanced disclosures to help financial statement users better understand significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of an entity’s portfolio. This standard is effective for the Company as a smaller reporting company beginning January 1, 2023. Adoption is not expected to have a material impact on the Company’s consolidated financial statement disclosure requirements.

In August 2018, FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820) – Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement, was issued to modify and enhance the disclosure requirements for fair value measurements. This update is effective in fiscal years, including interim periods, beginning after December 15, 2019, and early adoption is permitted. The Company is still completing its assessment of the impacts and anticipated adoption date of this guidance. Adoption is not expected to have a material impact on the Company’s consolidated financial statement disclosure requirements.

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740), Simplifying the Accounting for Income Taxes, which amends the approaches and methodologies in accounting for income taxes during interim periods and makes changes to certain income tax classifications. The new standard allows exceptions to the use of the incremental approach for intra-period tax allocation, when there is a loss from continuing operations and income or a gain from other items, and to the general methodology for calculating income taxes in an interim period, when a year-to date loss exceeds the anticipated loss for the year. The standard also requires franchise or similar taxes partially based on income to be reported as income tax and the effects of enacted changes in tax laws or rates to be included in the annual effective tax rate computation from the date of enactment. Lastly, in any future acquisition, the Company would be required to evaluate when the step-up in the tax basis of goodwill is part of the business combination and when it should be considered a separate transaction. The standard will be effective for the Company beginning January 1, 2021, with early adoption of the amendments permitted. The Company is currently evaluating the impact from the adoption of ASU 2019-12 on its consolidated financial statements.

Acquisitions

12 Months Ended

Dec. 31, 2019

Business Combinations [Abstract]

Acquisitions

3.Acquisitions

The Company entered into a definitive agreement to acquire all of the equity interests of Spitfire Pharma, Inc. (“Spitfire”) on July 8, 2019. Spitfire was a privately held, preclinical pharmaceutical company developing a novel dual GLP-1/glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis.

The transaction closed on July 12, 2019. The Company issued 1,887,250 unregistered shares of its common stock (the “shares”) as upfront consideration to certain former securityholders of Spitfire (collectively, the “Spitfire Equityholders”), representing an amount equal to $5,000,000 less working capital and transaction expense adjustment amounts as defined in the agreement (the “closing consideration”). The number of shares issued as payment of the Closing Consideration was determined based on the average of the closing prices of the Company’s common stock as reported on the Nasdaq Global Market for the twenty consecutive trading days prior to and including July 8, 2019, the date on which the parties entered into the Agreement and Plan of Merger and Reorganization (the “Merger Agreement”). The Spitfire Equityholders agreed to a lock-up on the upfront consideration pursuant to which 33.3% of the shares will be released at 6 months; 33.3% will be released at 12 months; and 33.3% will be released at 18 months.

The Merger Agreement also includes future contingent payments up to $88,000,000 in cash and shares of the Company’s common stock as follows (each, a “Milestone Event”):

•

a one-time payment of $5.0 million (the “IND Milestone Consideration Amount”) within sixty days of the submission of an Investigational New Drug Application (“IND”) to the United States Food and Drug Administration (the “FDA”) or other applicable governmental authority in a foreign jurisdiction, which IND has not been rejected or placed on clinical hold by the FDA or such applicable foreign governmental authority within time specified in the Merger Agreement; plus

•

a one-time payment of $3.0 million (together with the IND Milestone Consideration Amount, the “Regulatory Milestones”) within sixty days of the initiation of a human clinical trial of a product candidate anywhere in the world; plus

•

payments of up to $80.0 million upon the achievement of specified worldwide net sales (the “Sales Milestones”) of all products developed using the technology acquired in the License Agreement within ten years following the approval of a new drug application filed with the FDA.

The Company determined that the acquisition of Spitfire should be accounted for as an asset acquisition instead of a business combination because substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets, and therefore, the asset is not considered a business. The Company expensed the acquired intellectual property as of the acquisition date as in-process research and development with no alternative future uses. During the year ended December 31, 2019, the Company recorded an in-process research and development expense of $4,337,574 for the up-front consideration, which included the fair value of the common stock transferred and net liabilities assumed. The fair value of the common shares transferred was based on the Company’s stock price of $2.45 on July 12, 2019, offset by an estimated discount of $832,277 for lack of marketability.

The future contingent payments related to the Regulatory Milestones are stock-based payments accounted for under FASB Accounting Standards Codification Topic 480, Distinguishing Liabilities From Equity. Such stock-based payments are subject to a lock-up whereby 50% of the shares are released at 3 months and 50% are released at 6 months. As of the acquisition date, the Company estimated future contingent consideration based upon a Monte Carlo simulation that has been risk adjusted based on the probability of achieving the milestone and a discount for lack of marketability. The Company remeasured the fair value of the contingent consideration as of December 31, 2019. During the year ended December 31, 2019, the Company has expensed $2,750,000 to in-process research and development expenses.

The future contingent payments related to the Sales Milestones are predominately cash-based payments accounted for under FASB Accounting Standards Codification Topic 450, Contingencies. Accordingly, the Company will recognize the Sales Milestones when the contingency is resolved and the amount is paid or payable.

Finally, transaction costs associated with the Spitfire acquisition of $680,090 are recorded within research and development expense during the year ended December 31, 2019.

Net Loss Per Share

12 Months Ended

Dec. 31, 2019

Earnings Per Share [Abstract]

Net Loss Per Share

4.	Net Loss Per Share

Because the Company has reported net loss attributable to common stockholders for the years ended December 31, 2019 and 2018, basic and diluted net loss per share attributable to common stockholders are the same for both years. All preferred stock, unvested restricted stock, common stock warrants, stock options, and other potentially dilutive shares have been excluded from the computation of diluted weighted-average shares outstanding because such securities would have an antidilutive impact.

Potential common shares issuable upon conversion, unvested restricted stock, common stock warrants, stock options, and other potentially dilutive shares are excluded from the computation of diluted weighted-average shares outstanding are as follows:

	As of December 31,
	2019		2018
Common stock warrants		10,384,706		7,344,297
Common stock options		973,172		353,274
Unvested restricted stock		235,666		323,404
Other dilutive securities		28,070		—

Property and Equipment, Net

12 Months Ended

Dec. 31, 2019

Property Plant And Equipment [Abstract]

Property and Equipment, Net

5.	Property and Equipment, Net

Property and equipment, net consisted of the following:

	As of December 31,
	2019			2018
Furniture, fixtures and equipment	$	121,491		$	121,491
Laboratory equipment		926,590			926,590
Computers and telecommunications		150,517			149,290
Software		25,069			25,069
Leasehold improvements		1,228,108			1,228,108
Property and equipment, at cost		2,451,775			2,450,548
Less accumulated depreciation and amortization		(1,347,567	)		(1,107,746	)
Property and equipment, net	$	1,104,208		$	1,342,802

Depreciation expense related to property and equipment for the years ended December 31, 2019 and 2018 was $239,821 and $218,717, respectively.

Goodwill and Intangible Assets

12 Months Ended

Dec. 31, 2019

Goodwill And Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets

6.	Goodwill and Intangible Assets

The Company’s intangible assets consisted of the following:

	As of December 31, 2019
	Estimated Useful Lives	Gross Carrying Value		Accumulated Amortization			Impairment			Net Book Value
Internally developed patents	6 – 10 years	$	746,323	$	(448,874	)	$	—		$	297,449
Acquired licenses	16 – 20 years		285,000		(269,221	)		—			15,779
Total intangible assets subject to amortization		$	1,031,323	$	(718,095	)	$	—		$	313,228
IPR&D assets	Indefinite		13,418,967		—			(1,000,000	)		12,418,967
Total		$	14,450,290	$	(718,095	)	$	(1,000,000	)	$	12,732,195

	As of December 31, 2018
	Estimated Useful Lives	Gross Carrying Value		Accumulated Amortization			Impairment			Net Book Value
Internally developed patents	6 – 10 years	$	718,559	$	(317,172	)	$	—		$	401,387
Acquired licenses	16 – 20 years		285,000		(253,430	)		—			31,570
Total intangible assets subject to amortization		$	1,003,559	$	(570,602	)	$	—		$	432,957
IPR&D assets	Indefinite		37,868,978		—			(24,450,011	)		13,418,967
Total		$	38,872,537	$	(570,602	)	$	(24,450,011	)	$	13,851,924

Amortization expense of intangible assets subject to amortization totaled $147,500 and $83,652 for the years ended December 31, 2019 and 2018, respectively, and was classified as research and development expenses in the accompanying consolidated statements of operations and comprehensive loss.

As of December 31, 2019, future estimated amortization expense is as follows:

For the Year Ended December 31,
2020	$	42,275
2021		26,059
2022		26,059
2023		26,059
2024		22,153
2025 and thereafter		170,623
Total	$	313,228

The above future estimated amortization expense does not include potential amortization charges related to the remaining carrying value of IPR&D assets as of December 31, 2019. Those assets, which represent incomplete technologies, will be amortized to expense once the underlying technologies are substantially complete over their estimated useful lives, expected to be 15 to 18 years. In the event that in the future the Company ceases the development of these assets, the remaining carrying value would be written off at that time. IPR&D assets are periodically assessed for impairment by considering the state of completion of the projects, the remaining activities required to complete development, the anticipated market for the completed products, and anticipated future cash required to complete development.

During the fourth quarter of 2018, based on the continued decline of the Company’s market capitalization following the completion of the equity offerings and a strategic review of the development pipeline at the direction of a new CEO, the Company concluded under the qualitative assessment that an impairment indicator was present as it related to three IPR&D assets. Based on the Company’s strategic review, management concluded it would discontinue development of the Oncosyn cancer immunotherapy program and accordingly the entire amount of this IPR&D asset, or $3,061,011 was charged to expense. For the remaining two IPR&D assets related to HepTcell and SparVax-L, the Company calculated fair value using an excess earnings method or discounted cash flow model and compared the fair value to the carrying amount of the indefinite lived asset. Based on the analysis, the fair value of the Company’s HepTcell IPR&D asset exceeded its carrying value by an amount greater than 10%. However, during 2018, the Company concluded that the fair value of the SparVax-L IPR&D intangible asset was approximately $1,000,000 as compared to the current carrying value of the asset of $22,389,000, which resulted in an impairment charge of $21,389,000. Key assumptions used in the analysis included projected cash flows, a probability of success of the ultimate project, and the discount rate.

During 2019, as a result of the SparVax-L NIAID contract completion and the US government’s funding prioritization of only single dose anthrax vaccine candidates, we abandoned the project and concluded that the full remaining net book value of the SparVax-L IPR&D asset was impaired. As a result, of $1,000,000 was written off as an impairment charge which was classified as a component of operating expenses during the year ended December 31, 2019.

During the year ended December 31, 2018, an additional $490,676 of goodwill was written off as an impairment charge. The impairment was an adjustment to reduce the tax refund receivable acquired in connection with a 2017 business combination.

Changes in the carrying amounts of IPR&D assets and goodwill for the years ended December 31, 2019 and 2018 were:

	IPR&D			Goodwill
Balance, January 1, 2018	$	38,245,871		$	—
Additions		—			490,676
Foreign currency translation adjustments		(376,893	)		—
Impairment charges		(24,450,011	)		(490,676	)
Balance, December 31, 2018	$	13,418,967		$	—
Impairment charges		(1,000,000	)
Balance, December 31, 2019	$	12,418,967		$	—

Accrued Expenses and Other Current Liabilities

12 Months Ended

Dec. 31, 2019

Payables And Accruals [Abstract]

Accrued Expenses and Other Current Liabilities

7.	Accrued Expenses and Other Current Liabilities

Accrued expense and other current liabilities consist of the following:

	As of December 31,
	2019		2018
Accrued professional services	$	429,467	$	552,619
Accrued payroll and employee benefits		1,183,130		1,257,191
Accrued interest		5,047		1,192
Lease obligation, current portion		259,449		—
Deferred rent, current portion		—		175,490
Accrued research and development		1,966,111		2,076,704
Deferred revenue		61,563		19,753
Total accrued expenses	$	3,904,767	$	4,082,949

Licenses

12 Months Ended

Dec. 31, 2019

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Licenses

University of Alabama at Birmingham Research Foundation

The Company had an agreement with the University of Alabama at Birmingham Research Foundation (“UABRF”) for the exclusive worldwide license to develop, manufacture, and commercialize certain proprietary technology developed at UABRF. That agreement expired in accordance with its terms in January 2020. Under the terms of the amended and restated agreement, the Company was obligated to pay an annual license fee of $20,000 and low single digit royalty fees upon the commencement of product sales. Fees incurred under the UABRF agreement totaled $20,000 in each of the years ended December 31, 2019 and 2018 and are classified as a component of research and development expenses in the accompanying consolidated statements of operations and comprehensive loss.

Janssen Vaccines & Prevention B.V.

The Company has a royalty-bearing, worldwide non-exclusive license agreement with Janssen Vaccines & Prevention B.V. (“Janssen”) for use of its vaccine technology. We may terminate the license agreement without cause, and the agreement contains customary provisions for either party to terminate prior to the expiration of the agreement. The amended license agreement expires on a product-by-product and country-by-country basis on the later of the date upon which the last of the licensed patents applicable to the relevant product expires or 15 years from the date of first commercial sale of the relevant product. The Janssen patent rights include patents issued in the United States with an expected expiration date no earlier than April 2020, in each case not giving effect to any potential extensions and assuming payment of all associated fees. Upon expiration of the amended license agreement, or if we terminate the amended license agreement for Janssen’s material breach, we retain the right to exploit the rights granted. Under the agreement, the Company is required to pay an annual license fee and annual royalty fees upon reaching certain milestones in an amount that equals the greater of a low single digit percentage of net sales or $100,000. Fees incurred under the Janssen agreement totaled $111,499 and $177,625 for the years ended December 31, 2019 and 2018, respectively, and are included in research and development expenses in the accompanying consolidated statements of operations and comprehensive loss.

Auburn University

The Company has an exclusive, world-wide license agreement to develop, manufacture, and commercialize certain vaccine technology developed at Auburn University. The Auburn University agreement expires on the last of the related patent expiration date which may be extended upon patent renewal. The last of the patent expiration date is currently on August 15, 2025. Under the agreement, the Company paid an upfront fee of $1,000 upon signing of the agreement, and is obligated to pay an annual license fee of $5,000, and low single digit royalty fees from net product sales or sublicenses of the technology. Fees incurred under the Auburn University agreement totaled $5,000 in each of the years ended December 31, 2019 and 2018 and are included in research and development expenses in the accompanying consolidated statements of operations and comprehensive loss.

Notes Payable and Other Liabilities

12 Months Ended

Dec. 31, 2019

Notes Payable And Other Liabilities Disclosure [Abstract]

Notes Payable and Other Liabilities

9.	Notes Payable and Other Liabilities

The Company’s current portion of outstanding notes payable are summarized as follows:

	As of December 31,
	2019		2018
BPI France notes, short-term portion	$	—	$	71,596
Total notes payable	$	—	$	71,596

The Company’s long-term portion of outstanding notes payable as well as other long-term liabilities are summarized as follows:

	As of December 31,
	2019		2018
BPI France notes, long-term portion	$	—	$	501,174
Lease obligation, long-portion (see Note 15)		1,484,679		—
Deferred rent, long-term portion		—		1,045,807
Common stock warrant liability (see Note 12)		10,000		65,000
Economic conditional grants		250,000		100,000
Other		120,196		140,090
Total other long-term liabilities	$	1,864,875	$	1,852,071

BPI France Notes

The Company had two non-interest-bearing research and development funding arrangements with BPI France that were entered into in December 2013 to provide up to €750,000 in research funding in the first arrangement and up to €250,000 in the second arrangement. The Company was permitted to draw 50% of the funds upon the signing of the arrangements, an additional 30% contingent upon a financial audit and technical progress report, and the remaining amounts at the completion of the research and development project being funded by the arrangements. In October 2016, the Company and BPI France agreed to extend the term on the arrangement by two years. The total amount advanced under the arrangements was €500,000. In April 2019, the Company was notified that €102,951 exceeded the allowable funding in accordance with the arrangement and made payment of this amount on June 5, 2019. In September 2019, the Company was notified that €238,229 ($265,540) was converted into a grant and recognized as grant revenue for the year ended December 31, 2019. In October 2019, the Company paid the remaining balance on the BPI France notes. The total repayments during the year ended December 31, 2019 was $292,002.

Economic Incentive Grants

The Company has two conditional economic incentive grants for a total of $250,000 from Montgomery County and State of Maryland. The Montgomery County grant was received in May of 2018, with a term expiring on February 28, 2028. The State of Maryland grant was received in October 2019, with a 10-year term expiring on December 31, 2029. These grants are conditional primarily based on the Company maintaining its current headquarter locations in addition to employing a required number of employees at different reporting dates through the term of the grant. The Company is accruing 3% interest on both grants and has recorded $5,042 in interest expense for the year ended December 31, 2019.

Exchange Notes

In conjunction with the First Exchange (as defined in Note 12) the Company issued convertible notes (the “Exchange Notes”) with an aggregate principal value of $1,500,000, which were initially convertible into up to 73,530 shares of our common stock at the note holder’s option on the maturity date. The Exchange Notes were also convertible in the event of default, at which time the balance of the notes would increase by 112% and was convertible at a share price equal to the lower of $20.40 per share or 75% of the weighted average price of common stock during the twenty consecutive trading day period immediately preceding the event of default. In the event the weighted average price of common stock as defined above is below $4.50 per share, then a supplemental cash payment was due to the note holder.

The conversion and redemption options embedded in the Exchange Notes qualified for derivative accounting under ASC 815-15 “Derivatives and Hedging”. The fair value of the derivative liability at the date of issuance resulted in a discount to the Exchange Notes of $180,611 which was accreted into interest expense over the term of the convertible note. Debt issuance costs of $58,172 were capitalized and was recognized in interest expense over the term of the notes. In addition, the Company paid the holders of the Exchange Notes and additional $54,226 of interest earned. During the year ended December 31, 2018, total interest expense recognized on the Exchange Notes was $293,009.

The Company fully redeemed the Exchange Notes and accrued interest for cash in October 2018.

Preferred Stock

12 Months Ended

Dec. 31, 2019

Equity [Abstract]

Preferred Stock

10.	Preferred Stock

Redeemable Convertible Preferred Stock

On August 16, 2017, the Company issued 15,656 shares of $0.0001 par value, redeemable preferred stock and warrants to purchase up to 78,181 shares of common stock (see Note 12), for total gross proceeds of $14,716,370, and incurred issuance costs totaling $1,697,800. The redeemable preferred stock matured on August 16, 2018. In addition, the redeemable preferred stock agreements required that the Company reserve a sufficient number of common shares to cover at least 150% of the common shares expected to be issued upon the conversion of the redeemable preferred stock at the then current conversion price, and the exercises of common stock warrants issued in connection with the redeemable preferred stock.

Because the securities contained contingencies which could require the Company to redeem the shares for cash, and such contingencies were outside the control of the Company, the redeemable preferred stock was classified outside of permanent equity. Because a substantive conversion feature was also present at issuance, the redeemable preferred stock is only contingently redeemable and therefore prior to its redemption or conversion was classified as temporary equity and carried on the balance sheet in between liabilities and equity at its accreted redemption value.

In addition, certain features present in the redeemable preferred stock required separate recognition. For purposes of this evaluation, the Company determined that the redeemable preferred instrument is more akin to a debt host because the installment conversion feature, as the primary settlement mechanism, is indexed to an underlying other than interest rates or credit risk and settles in variable shares. Because the potential contingent redemption price contained a significant premium over the issuance price, the redemption feature is considered to be not clearly and closely related to the debt-like host instrument. All redemption features (including the change of control redemption, triggering event redemption, mandatory redemption, and installment redemption) were determined to be a single, compound embedded derivative financial instrument to be bifurcated and separately accounted for as a liability. The embedded derivative financial instrument was initially recorded at its fair value on the redeemable preferred stock issuance date and was being remeasured on each subsequent balance date with changes in fair value classified as a component of other income (expenses), net. The embedded derivative was classified as a component of other long-term liabilities until its expiration with the conversion of the last amount of redeemable preferred stock.

The redeemable preferred stock also contained a beneficial conversion feature at issuance. The conversion feature was “in-the-money” as of the commitment date as the fair value of the underlying common share was greater than the effective conversion price. The beneficial conversion feature, measured as the intrinsic value of the feature, totaled $1,506,196 on the redeemable preferred stock issuance date, and was classified as a component of additional paid-in capital. The beneficial conversion feature was not remeasured in subsequent periods but was recognized in nine equal amounts corresponding to each of the redeemable preferred stock installments. During the year ended December 31, 2018, the Company recognized $1,338,840 of the beneficial conversion feature.

The fair value used to determine the initial carrying value of the embedded redemption derivative financial instrument was measured using Level 3 inputs and was estimated using the Monte Carlo simulation valuation model. The periodic changes in the fair value of the embedded redemption derivative financial instrument for the year ended December 31, 2018 are as follows:

Balance, January 1, 2018	$	27,236
Changes in fair value		(27,236	)
Balance, December 31, 2018	$	—

During the year ended December 31, 2018, the Company converted 9,813 shares of the redeemable preferred stock for an aggregate of 502,078 shares of common stock. In June 2018, the Company additionally agreed to redeem the First Exchange investors’ remaining 2,364 shares of Series B Preferred Stock at their face value of $2,364,044. Since the redemption occurred prior to the stated maturity date, $56,792 of the redemption price is considered a deemed dividend. On July 11, 2018, the Company entered into exchange agreements with certain other holders of the Series B Preferred Stock and warrants (the “Second Exchange”) pursuant to which the Company (i) issued an aggregate of 32,124 shares of common stock and (ii) paid $22,241 in cash, in exchange for all of their outstanding shares of our Series B Preferred Stock. Due to the redemption occurring prior to the stated maturity date, this exchange resulted in a deemed contribution of $111,553. As of December 31, 2019 and 2018, there were no remaining Redeemable Convertible Preferred Shares outstanding.

Common Stock

12 Months Ended

Dec. 31, 2019

Text Block [Abstract]

Common Stock

11.	Common Stock

On September 26, 2018, the Company issued an aggregate of 286,633 shares of common stock at a purchase price of $17.02 per share to certain institutional investors in a registered direct offering (the “First Registered Direct Offering”). The net proceeds of the First Registered Direct Offering were $4,334,816, after deducting placement agent fees and offering expenses of $543,677.

On October 2, 2018, the Company issued a combined total of 2,400,000 common units and pre-funded units in a public offering (the “Unit Offering”). Each common unit in the Unit Offering was sold at a public offering price of $5.00 and consisted of one share of common stock and a warrant to purchase one share of common stock at an exercise price of $6.00. Each warrant sold in the Unit Offering was exercisable immediately and expired five years from the date of issuance. Each pre-funded unit in the Unit Offering was sold at a public offering price of $4.99 and consisted of a pre-funded warrant to purchase one share of common stock at an exercise price of $0.01 per share and a warrant to purchase one share of common stock at an exercise price of $6.00. The pre-funded warrants were immediately exercisable and were able to be exercised at any time until all of the pre-funded warrants were exercised in full. All of the pre-funded warrants were exercised prior to December 31, 2018. The net proceeds of the Unit Offering were $10,667,506, after deducting the underwriting discount and estimated offering expenses payable by the Company. The entire amount of 2,400,000 common shares issued in connection with the Unit Offering are included in common shares outstanding.

The warrants issued in the Unit Offering are each subject to anti-dilution protection. Accordingly, to the extent the Company was to issue additional common stock or securities convertible into common stock at an issuance price lower than exercise price of the warrants, the exercise price of the warrants would be adjusted to the lower of (i) the issuance price or (ii) the lowest volume weighted average price of the Company’s common stock on the five trading days following the announcement of the new offering.

On October 10, 2018, the Company issued a combined total of 4,629,630 common units and pre-funded units to certain institutional investors in a registered direct offering (the “Second Registered Direct Offering”). Each common unit in the Second Registered Direct Offering was sold at a price of $5.40 and consisted of one share of common stock and a warrant to purchase one share of common stock at an exercise price of $5.40. Each warrant sold in the Second Registered Direct Offering was exercisable immediately and expired five years from the date of issuance. Each pre-funded unit in the Second Registered Direct Offering was sold at a public offering price of $5.39 and consisted of a pre-funded warrant to purchase one share of common stock at an exercise price of $0.01 per share and a warrant to purchase one share of common stock at an exercise price of $5.40. The pre-funded warrants were immediately exercisable and were able to be exercised at any time until all of the pre-funded warrants are exercised in full. All of the pre-funded warrants were exercised prior to December 31, 2018. The net proceeds of the Second Registered Direct Offering were $22,400,673, after deducting the underwriting discount and estimated offering expenses payable by the Company. The entire amount of 4,629,630 common shares issued in connection with the Unit Offering are included in common shares outstanding.

On March 12, 2019, the Company issued a combined total of 4,361,370 common units and pre-funded units to certain institutional investors in a registered direct offering (the “Third Registered Direct Offering”). Each common unit in the Third Registered Direct Offering was sold at a price of $3.21 and consisted of one share of common stock and 0.70 of a warrant to purchase one share of common stock at an exercise price of $3.21. Each warrant sold in the Third Registered Direct Offering was exercisable immediately and expired five years from the date of issuance. Each pre-funded unit in the Third Registered Direct Offering was sold at a public offering price of $3.20 and consisted of a pre-funded warrant to purchase one share of common stock at an exercise price of $0.01 per share and 0.70 of a warrant to purchase one share of common stock at an exercise price of $3.21. All of the pre-funded warrants were exercised prior to March 31, 2019. The net proceeds of the Third Registered Direct Offering were $12,668,784, after deducting the underwriting discount and estimated offering expenses payable by the Company.

The warrants issued in both the Unit Offering and the Second Registered Direct Offering were concluded to be equity classified freestanding financial instruments. The Second Registered Direct Offering triggered a down round adjustment to the exercise price of the warrants issued in the Unit Offering from $6.00 to $4.1798. The value of a down round feature is measured as the difference between the financial instrument’s fair value (without the down round feature) using the pre-trigger exercise price and the financial instrument’s fair value (without the down round feature) using the reduced exercise price. During the year ended December 31, 2018, the Company treated the value of the effect of the reduction in exercise price as a deemed dividend of $780,038 which reduced income available to common shareholders.

The warrants issued in the Third Registered Direct Offering were also concluded to be equity classified freestanding financial instruments. The Third Registered Direct Offering triggered an additional down round adjustment to the exercise price of the warrants issued in the Unit Offering from $4.1798 to $2.7568. During the year ended December 31, 2019, the Company treated the value of the effect of the reduction in exercise price as a deemed dividend of $452,925 which reduced income available to common shareholders.

On July 12, 2019, as discussed in Note 3, the Company issued 1,887,250 unregistered shares of its common stock as upfront consideration to certain former Spitfire Equityholders representing the closing consideration.

Warrants

12 Months Ended

Dec. 31, 2019

Equity [Abstract]

Warrants

12.

Warrants

The following common stock warrants were outstanding at December 31, 2019:

Number of

Common

Stock

Warrants

Per Share

Exercise

Price

Issuance Date

Expiration Date

Replacement warrants

155

483.00

March 3, 2012

March 3, 2022

Issued with redeemable preferred stock*

80.10

August 16, 2017

August 16, 2022

Issued with common units in Unit Offering

2,505,250

2.75

October 2, 2018

October 2, 2023

Underwriter warrant issued with public offering

196,650

6.25

October 2, 2018

September 28, 2021

Issued with common units in the Second Registered Direct Offering

4,629,630

5.40

October 10, 2018

October 10, 2023

Issued with common units in the Third Registered Direct Offering

3,052,959

3.21

March 12, 2019

March 12, 2024

Total

10,384,706

*Liability classified warrants

The following common stock warrants were outstanding at December 31, 2018:

Number of

Common

Stock

Warrants

Per Share

Exercise

Price

Issuance Date

Expiration Date

Replacement warrants

155

483.00

March 3, 2012

March 3, 2022

Issued with redeemable preferred stock*

1,612

80.10

August 16, 2017

August 16, 2022

Issued with common units in Unit Offering

2,516,250

4.18

October 2, 2018

October 2, 2023

Underwriter warrant issued with public offering

196,650

6.25

October 2, 2018

September 28, 2021

Issued with common units in the Second Registered Direct Offering

4,629,630

5.40

October 10, 2018

October 10, 2023

Total

7,344,297

*Liability classified warrants

In May 2017, the Company issued 155 common stock warrants to replace outstanding common stock warrants in connection with the Merger Agreement.

In August 2017, in connection with the redeemable preferred stock issuance (Note 10), the Company granted warrants to holders of redeemable preferred stock to purchase up to 78,181 shares of the Company’s common stock. Warrants issued with the redeemable preferred stock are classified as a liability and are initially recorded at their grant date fair value, to be remeasured on each subsequent balance sheet date. The warrant liability is classified as component of other long-term liabilities. During the years ended December 31, 2019, and 2018, the Company exchanged 1,550 and 76,569, respectively, of these warrants for a combination common stock and cash, leaving 62 of these warrants outstanding as of December 31, 2019.

On June 29, 2018 the Company closed on privately negotiated exchange agreements with certain investors to exchange warrants to purchase 53,125 common shares of the Company (the “First Exchange”) in exchange for:

(i)

167,700 shares of the Company’s common stock valued at approximately $12.60 per share;

(ii)

Convertible notes with an initial aggregate principal balance of $1,500,000 (Note 9), and;

(iii)

$1,100,000 in cash consideration.

The total fair value of the consideration given in exchange for the warrants in the First Exchange was $4,727,000, which exceeded the March 31, 2018 fair value of the warrants by $3,467,935. The warrant fair value at March 31, 2018 was determined assuming an orderly transaction between market participants, using a Monte Carlo simulation valuation model. The Company was compelled to enter into the exchange transaction as management believes the dilutive features of the common stock warrants prevented the Company from obtaining sufficient financing on acceptable terms. Accordingly, the Company recorded a loss on exchange of warrants in the First Exchange of $3,593,082, inclusive of transaction costs of $125,147, which is reported in changes in fair value of warrant liability including loss on exchange on the consolidated statement of operations and comprehensive loss. The Company additionally agreed to redeem the First Exchange investors’ remaining shares of Series B Preferred Stock at their face value of $2,364,044 (Note 10).

The value of the shares of the Company’s common stock which were part of the First Exchange consideration were valued at a 5% discount to the June 29, 2018 closing price. This amount is considered a marketability discount calculated based on an analysis of the leak out provision provided for in the exchange agreements. The key assumptions used in calculating the marketability discount were:

Holding period, in years	0.03
Risk free rate	1.77	%
Dividend yield	0	%
Volatility	109.9	%

On July 11, 2018, the Company entered into exchange agreements with certain other holders of the redeemable preferred stock and warrants (the “Second Exchange”) pursuant to which we (i) issued an aggregate of 32,124 shares of common stock and (ii) paid $22,241 in cash, in exchange for all of the outstanding shares of our Series B Preferred Stock (Note 10). We additionally issued 145,038 shares of common stock in exchange for warrants to purchase 22,523 shares of common stock. Consideration for the Series B Preferred Stock was transferred to the holders on July 11, 2018. Consideration for the warrant exchange was subject to shareholder approval which the Company obtained at its annual shareholder meeting on August 30, 2018, and the shares of common stock were subsequently transferred to the holders on September 12, 2018.

On September 7, 2018, the Company closed on exchange agreements with certain holders of our warrants (the “Third Exchange”) pursuant to which we issued 5,929 shares of common stock in exchange for warrants to purchase 921 shares of common stock.

The consideration given for the warrants in the Second and Third Exchange was valued at the closing price of the common stock on the day the transactions closed and the shares were transferred, which was $8.64 and $8.85 per share, respectively. Accordingly, the Company realized a gain on the exchange of warrants of $779,923 based on the fair value of the shares transferred as compared to the last determination of fair value of the warrants performed by the Company as of June 30, 2018, which is reported in changes in fair value of warrant liability including loss on exchange on the consolidated statement of operations and comprehensive loss. The following is a summary of the income statement effect of changes in the Company’s outstanding warrants:

	Year Ended December 31,
	2019		2018
Changes in fair value of warrants	$	30,000	$	(9,160	)
Loss on warrants exchanged		—		(2,688,012	)
Transaction costs		—		(181,312	)
Change in fair value of warrant liability, including gain (loss) on exchange	$	30,000	$	(2,878,484	)

A summary of warrant activity during the years ended December 31, 2019 and 2018 is as follows:

	Year Ended December 31,
	2019			2018
Warrants outstanding, January 1		7,344,297			78,336
Issuances		3,052,959			7,342,530
Exercises, conversions, exchanges and repurchases		(12,550	)		(76,569	)
Warrants outstanding, December 31		10,384,706			7,344,297

The periodic changes in the fair value of the warrant liability is as follows:

Balance, January 1, 2018	$	3,400,869
Warrants settled upon exchange		(3,345,029	)
Changes in fair value		9,160
Balance, December 31, 2018		65,000
Warrant repurchases		(25,000	)
Changes in fair value		(30,000	)
Balance, December 31, 2019	$	10,000

The following assumptions were used to estimate the fair value of warrants classified as a liability using the Monte Carlo simulation valuation model with Level 3 inputs at December 31, 2019 and 2018 were as follows:

	As of December 31,
	2019			2018
Expected volatility		89.87	%		93.90	%
Expected term (years)		2.63			3.60
Risk-free interest rate		1.61	%		2.48	%
Expected dividend yield		0.00	%		0.00	%

Stock-Based Compensation

12 Months Ended

Dec. 31, 2019

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-Based Compensation

13.	Stock-Based Compensation

Stock Options

The Company established the 2001 Employee Stock Option Plan to provide incentive stock options and non-qualified stock options to employees, and the 2001 Non-employee Stock Option Plan to provide non-qualified stock options to the members of the board of directors and advisory board, and non-employees. The 2001 Employee Stock Option Plan and the 2001 Non-employee Stock Option Plan are collectively referred to as the “2001 Plans.” In connection with the Merger Agreement in 2017, the Company issued options from its 2001 Plans to replace options previously granted option plans. The Company de-designated common stock available for issuance under the 2001 Plans. No additional options or restricted stock will be granted under these plans. Options outstanding and unvested restricted stock granted or replaced under these plans will continue to vest over the remaining vesting period through the earlier of exercise, expiration, or forfeiture no additional options, restricted stock or other awards will be granted under these plans. The replacement options issued after the 2017 mergers will continue to vest over the remaining vesting period through the earlier of exercise, expiration, or forfeiture. Also, in connection with the 2017 mergers, the 2001 Plans were assumed by the Company.

In addition, the Company assumed the PharmAthene, Inc. Amended and Restated 2007 Long-Term Incentive Compensation Plan, or the 2007 Plan. Awards outstanding under the 2007 Plan remained outstanding in accordance with their applicable terms and conditions. No additional awards will be made under the 2007 Plan.

The Company established the 2017 Omnibus Incentive Plan (the “Omnibus Plan”) to provide incentive stock options, non-qualified stock options, restricted stock, and other stock-based awards denominated in shares of the Company’s common stock, and performance-based cash awards to eligible employees, consultants, and directors. In 2018, the Company’s shareholders approved an amendment to the Omnibus Plan to increase the number of shares reserved for issuance from 1,500,000 to 5,000,000. The aggregate share reserve will be increased on January 1 of each year commencing in 2018 and ending on and including January 1, 2027 up to an amount equal to the lowest of (i) 4% of the total number of shares of common stock outstanding on a fully diluted basis as of December 31 of the immediately preceding calendar year, and (ii) such number of shares of common stock, if any, determined by the Company’s board of directors. The maximum shares of common stock that may be granted to each employee or consultant in any fiscal year under the Omnibus Plan is the lesser of 800,000 shares per type of award or a maximum compensation amount of $5,000,000 under a Black-Scholes valuation model. The maximum common stock that may be granted to directors under the Omnibus Plan during any fiscal year is 500,000 shares.

On November 29, 2018, the Board approved and adopted the Altimmune Inc. 2018 Inducement Grant Plan (the “Inducement Plan”). The Inducement Plan provides for the grant of equity or equity-based awards in the form of non-qualified stock options, restricted stock awards, and other stock-based awards. The Inducement Plan was adopted by the Board without stockholder approval pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.

The Board has reserved 2,000,000 shares of the Company’s common stock for issuance pursuant to awards granted under the Inducement Plan (subject to customary adjustments in the event of a change in capital structure of the Company), and the Inducement Plan will be administered by the Compensation Committee. In accordance with Rule 5635(c)(4) of the NASDAQ Listing Rules, awards under the Inducement Plan may be only made to an employee who has not previously been an employee or member of the Board or any parent or subsidiary, or following a bona fide period of non-employment by the Company or a parent or subsidiary, if he or she is granted such award in connection with his or her commencement of employment with the Company or a subsidiary and such grant is an inducement material to his or her entering into employment with the Company or such subsidiary.

The 2001 Plans, the 2007 Plan, the Omnibus Plan, and the Inducement Plan are collectively referred to as the “Plans.” During the year ended December 31, 2019 under the Plans, a total of 725,000 options to purchase shares of common stock were granted. As of December 31, 2019, there were 83,373 and 1,491,582 shares of common stock available for future grants under the Omnibus Plan and the Inducement Plan, respectively.

The fair value of stock option issued to employees was estimated at the date of grant using Black-Scholes with the following weighted-average assumptions:

	For the Year Ended December 31,
	2019			2018
Expected volatility		92.68	%		92.14	%
Expected term (years)		5.89			6.07
Risk-free interest rate		2.17	%		2.86	%
Expected dividend yield		0.00	%		0.00	%

Expected volatility: As there is not sufficient historical volatility for the expected term of the stock options, the Company uses an average historical share price volatility, inclusive of its own volatility, based on an analysis of reported data for a peer group of comparable companies which were selected based upon industry similarities.

Expected term (years): Expected term represents the number of years that the Company’s option grants are expected to be outstanding. There is not sufficient historical share exercise data to calculate the expected term of the stock options, therefore, the Company elected to utilize the simplified method to value option grants. Under this approach, the weighted average expected life is presumed to be the average of the vesting term and the contractual term of the option.

Risk-free interest rate: The Company determined the risk-free interest rate by using a weighted-average equivalent to the expected term based on the daily U.S. Treasury yield curve rate in effect as of the date of grant.

Expected dividend yield: The Company does not anticipate paying any dividends in the foreseeable future.

The fair value of each non-employee stock option is estimated at the date of grant using Black-Scholes with assumptions generally consistent with those used for employee stock options, with the exception of expected term, which is over the contractual life.

A summary of stock option activities under the Plans is presented below:

	Number of Stock Options			Weighted- Average Exercise Price		Weighted-Average Remaining Contractual Term (Year)		Weighted- Average Intrinsic Value
Outstanding, January 1, 2019		353,274		$	10.97		6.04	$	-
Granted		725,000			2.67
Exercised		—						$	-
Forfeited or expired		(105,102	)		14.89
Outstanding, December 31, 2019		973,172		$	4.36		5.91	$	-
Exercisable, December 31, 2019		289,518		$	6.86		5.48	$	-
Expected to vest, December 31, 2019		594,779		$	3.30		6.09	$	-

The per share weighted-average grant date fair value of stock options granted during the years ended December 31, 2019 and 2018 were $2.67 and $4.63, respectively. At December 31, 2019, there was $1,375,808 of unrecognized compensation cost related to stock options, which is expected to be recognized over a weighted-average period of 3.22 years.

Restricted Stock

In October 2016, the Company authorized and granted a restricted stock award of 2,651 shares at an aggregate purchase price of $1,067. The weighted average grant date fair value of the restricted stock award was $310.80 per share. The restricted stock vests ratably at the end of each quarter over four years starting on December 31, 2016 with 50% of the original issued shared subject to accelerated vesting upon a deemed liquidation event. Fair value of restricted shares that vested during the year ended December 31, 2019 totaled $648. The Company expects the 213 remaining shares to vest during 2020.

On November 30, 2018, the Company authorized and granted one executive officer a restricted stock award of 322,907 shares. The weighted average grant date fair value of the restricted stock award was $3.59 per share. The restricted stock vests over a four-year period, 25% of the Shares vesting on the one-year anniversary, and the remaining 75% vesting in 36 substantially equal monthly installments and will be fully vested on December 1, 2022; provided, however, that the executive officer has not experienced a termination prior to the applicable vesting date. Fair value of the 87,454 restricted shares that vested during the year ended December 31, 2019 totaled $159,032.

A summary of restricted stock activities is presented below:

	Shares			Weighted- average Grant Date Fair Value
Unvested, January 1, 2019		323,404		$	4.06
Vested		(87,738	)		4.58
Unvested, December 31, 2019		235,666		$	3.87

As of December 31, 2019, total unrecognized compensation expense related to restricted stock awards was $843,770, which the Company expects to recognize over a weighted average period of approximately 2.92 years.

2019 Employee Stock Purchase Plan

On March 29, 2019, the board of directors adopted the 2019 Employee Stock Purchase Plan (the “2019 ESPP”). A total of 403,500 shares of the Company’s common stock have been reserved for issuance under the 2019 ESPP. Subject to any plan limitations, the 2019 ESPP allows eligible employees to contribute through payroll deductions up to 10% of their earnings for the purchase of the Company’s common stock at a discounted price per share. The offering periods begin in February and August of each year, with the initial offering period starting on August 1, 2019. The common shares issuable under the 2019 ESPP were registered pursuant to a registration statement on Form S-8 on April 4, 2019.

Unless otherwise determined by the administrator, the Company’s common stock will be purchased for the accounts of employees participating in the 2019 ESPP at a price per share that is the lesser of 85% of the fair market value of the Company’s common stock on the first trading day of the offering period or 85% of the fair market value of the Company’s common stock on the last trading day of the offering period. The ESPP estimated shares to be purchased fair value is included in the stock-based compensation expense.

Employees have the ability to purchase shares of the Company’s common stock at the lower of the first or last trading day of the offering period, which represents an option and, therefore, the ESPP is a compensatory plan under ASC 718-50, Employee Stock Purchase Plans. Accordingly, stock-based compensation expense is determined based on the option’s grant-date fair value, employee contributions, and the Company’s stock price and is recognized over the requisite service period of the option. The Company used the Black-Scholes valuation model and recognized stock-based compensation expense of $21,608 for the year-ended December 31, 2019.

Stock-based Compensation Expense

Stock-based compensation expense is classified in the accompanying consolidated statements of operations and comprehensive loss for the years ended December 31, 2019 and 2018 as follows:

	Year-Ended December 31,
	2019		2018
Research and development	$	356,718	$	319,354
General and administrative		907,513		453,894
Total	$	1,264,231	$	773,248

Income Taxes

12 Months Ended

Dec. 31, 2019

Income Tax Disclosure [Abstract]

Income Taxes

14.	Income Taxes

The components of net loss before income tax benefit are as follows:

	Year Ended December 31,
	2019		2018
U.S. operations	$	18,562,738	$	38,979,638
Non-U.S. operations		2,015,893		6,341,308
Net loss before income tax benefit	$	20,578,631	$	45,320,946

The components of the income tax benefits are as follows:

	Year Ended December 31,
	2019		2018
U.S. federal
Current	$	—	$	271,356
Deferred		45,465		4,309,534
US state and local
Current		—		(1,464	)
Deferred		13,035		1,570,368
Income tax benefit	$	58,500	$	6,149,794

Reconciliation between the effect of applying the federal statutory rate and the effective income tax rate used to calculate the Company’s income tax benefit is as follows:

	Year Ended December 31,
	2019			2018
Federal statutory rate		21.00	%		21.00	%
State income taxes, net of federal benefit		3.12			4.53
Foreign income tax rate differential		(0.01	)		(0.15	)
Stock compensation		(0.93	)		(0.16	)
Research and development tax credit		(1.51	)		(1.30	)
Acquisition costs		(0.91	)		—
Goodwill impairment		—			(0.22	)
Acquired in process research and development impairment		(7.03	)		—
Loss on warrant exchange and warrant FMV changes		0.03			(1.33	)
Permanent differences and other		(0.99	)		2.14
Change in valuation allowance		(12.49	)		(10.94	)
Effective tax rate		0.28	%		13.57	%

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income and for tax carryforwards. Significant components of the Company’s deferred tax assets and liabilities are as follows:

	December 31,
	2019			2018
Deferred tax assets:
Domestic NOLs	$	8,141,204		$	4,025,587
Foreign NOLs		5,352,556			5,303,154
Accrued expenses		208,604			162,814
Amortization		947,115			1,035,765
Deferred revenue		44,558			38,494
Stock compensation		622,789			568,165
Deferred rent		—			336,070
Lease Liability		479,940			—
Research and development carryforward		73,155			73,156
Total deferred tax assets		15,869,921			11,543,205
Deferred tax liabilities:
IPR&D assets		(2,373,304	)		(2,557,085	)
Right of Use Asset		(192,160	)		—
Depreciation		(154,678	)		(205,859	)
IRC §481(a) adjustment		—			—
Total deferred tax liabilities		(2,720,142	)		(2,762,944	)
Deferred tax assets, net		13,149,779			8,780,261
Valuation allowance		(13,149,779	)		(8,838,761	)
Total deferred tax liabilities net	$	—		$	(58,500	)

The Company assesses the need for a valuation allowance against our deferred tax assets and considers both positive and negative evidence related to the likelihood of realization of the deferred tax assets to determine, based on the weight of available evidence, whether it is more-likely-than-not that some or all of the deferred tax assets will not be realized. This determination requires significant judgment, including assumptions about future taxable income that are based on historical and projected information. The increase in the valuation allowance during the year ended December 31, 2019 primarily relates to increases for current year losses in both the U.S. and foreign locations which the Company concluded needed a full valuation allowance. The Company has recorded a valuation allowance against its gross U.S. deferred tax assets it believes are not more likely than not realizable and the net non-U.S. deferred tax assets. Deferred tax liabilities, consist primarily of indefinite life IPR&D assets located in a foreign subsidiary, which will be applied in the future to offset against NOLs that have an unlimited life.

The Company has U.S. federal net operating loss carryforwards of approximately $29,596,042 as of December 31, 2019. Of this amount, $6,576,869 has a 20-year carry forward period that will expire at various dates beginning in 2021. Under current law, the remaining amount of $23,019,173 has an unlimited life.

As of December 31, 2019 and 2018, the Company does not have any material unrecognized tax benefits. The Company files income tax returns in the United States, various U.S. states, U.K., and France. The Company is still open to examination by the applicable taxing authorities from 2009 forward, although tax attributes that were generated prior to 2009 may still be adjusted upon examination by federal, state, foreign, or local tax authorities if they either have been or will be used in a future period. Under Section 382 of the Internal Revenue Code of 1986, as amended, substantial changes in the Company’s ownership may limit the amount of NOLs that can be utilized annually in the future to offset its U.S. federal and state taxable income. Specifically, this limitation may arise in the event of a cumulative change in ownership of the Company of more than 50% within any three-year period. The amount of the annual limitation is determined based on the value of the Company immediately before the ownership change. The Company has reduced the NOL and related valuation allowance in both 2018 and 2019 and subsequent ownership changes may further affect the limitation in future years.

Lease Obligations

12 Months Ended

Dec. 31, 2019

Leases [Abstract]

Lease Obligations

15.Lease Obligations

The Company rents office and laboratory space in the United States. The Company also leases office equipment under a non-cancellable equipment lease through December 2022. Rent expense during the years ended December 31, 2019 and 2018 under all of the Company’s operating leases was $346,603 and $632,658, respectively, which includes short-term leases and variable lease costs not included in the lease obligation.

The office space lease provides for increases in future minimum annual rental payments as defined in the lease agreements. The Company has determined the lease renewal option is not reasonably certain.

The office space lease provided the Company tenant improvement incentives and allowances. The Company recorded $164,090 and $115,782 of amortization of lease incentive obligation as a reduction of rent expense for the years ended December 31, 2019 and 2018, respectively.

The cash paid for operating lease liabilities for the year ended December 31, 2019 was $380,805.

Supplemental other information related to the operating leases balance sheet information is as follows:

	December 31, 2019
Operating lease obligations	$	1,744,128
Right of use asset	$	698,321
Weighted-average remaining lease term		5.33
Weighted-average discount rate		8.0	%

Maturities of lease liabilities are as follows:

Year ending December 31,
2020	$	387,079
2021		393,542
2022		400,198
2023		407,054
2024		414,117
2025 and thereafter		138,831
Total lease payments		2,140,821
Less imputed interest		(396,693	)
Total	$	1,744,128

Commitments and Contingencies

12 Months Ended

Dec. 31, 2019

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

16.	Commitments and Contingencies

See Note 8 for the Company’s commitments under license agreements.

As disclosed in Note 3, the Company is obligated to make payments of up to $80.0 million upon the achievement of specified worldwide net sales of all products developed using the technology acquired from Spitfire Pharma Inc. within ten years following the approval of a new drug application filed with the FDA.

In December 2019, a complaint was filed by Dr. De-Chu Christopher Tang (“Plaintiff”) against the Company in U.S. District Court for the Eastern District of Texas. The Plaintiff amended the complaint in February 2020 to include Vipin K. Garg and David J. Drutz as defendants, in addition to the Company (Dr. Garg, Dr. Drutz, and the Company are collectively referred to as “Defendants”). In March 2020 the Defendants’ filed a motion to dismiss the complaint. Subsequently the Plaintiff filed a motion to strike Defendants’ motion to dismiss and both motions are currently pending. Plaintiff, who is representing himself, alleges five causes of action as follows: (1) Defendants’ alleged retention of Plaintiff’s lab notebooks; (2) alleged plagiarism based on publishing an article without naming Plaintiff as an author; (3) use of the Adhigh System, which Plaintiff alleges he developed; (4) allegations that Defendants manipulated the Company’s stock and caused a decrease in value; and (5) allegations that the Defendants “wast[ed] government grant money and poison[ed] science by leaving data to rot.” The Company believes the allegations in the complaint are without merit and intends to vigorously defend the litigation. However, the outcome of this legal proceeding is uncertain at this time and the Company cannot reasonably estimate a range of loss, if any. Accordingly, the Company has not accrued any liability associated with this action. The Company is a party in various other contractual disputes, litigation, and potential claims arising in the ordinary course of business. The Company does not believe that the resolution of these matters will have a material adverse effect on its financial position or results of operations.

Fair Value Measurement

12 Months Ended

Dec. 31, 2019

Fair Value Disclosures [Abstract]

Fair Value Measurement

17.	Fair Value Measurement

The Company records cash equivalents, short-term investments, contingent consideration, and warrant liability at fair value on a recurring basis. Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants based on assumptions that market participants would use in pricing an asset or liability. As discussed in Note 2, the Company classifies assets and liabilities measured at fair value using the fair value hierarchy per ASC 820.

The Company’s assets and liabilities measured at fair value on a recurring basis at December 31, 2019 consisted of the following:

	Fair Value Measurement at December 31, 2019
	Total		Level 1		Level 2		Level 3
Recurring fair value measurements
Cash equivalents - money market funds	$	8,034,640	$	8,034,640	$	—	$	—
Short-term investments		28,277,386		—		28,277,386		—
Contingent consideration		2,750,000		—		—		2,750,000
Warrant liability		10,000		—		—		10,000

The Company’s assets and liabilities measured at fair value on a recurring basis at December 31, 2018 consisted of the following:

	Fair Value Measurement at December 31, 2018
	Total		Level 1		Level 2		Level 3
Recurring fair value measurements
Cash equivalents — money market fund	$	29,375,509	$	29,375,509	$	—	$	—
Warrant liability		65,000		—		—		65,000

Cash equivalents and short-term investments valued using publicly quoted market prices, data from third party pricing services, and other market observable data at the end of each reporting period. Short-term investments had quoted prices at December 31, 2019 as shown below:

	As of December 31, 2019
	Amortized Cost		Unrealized Gain		Market Value

United States treasury securities	$	3,394,579	$	3,228	$	3,397,807
Corporate debt securities		24,862,800		16,779		24,879,579
Total	$	28,257,379	$	20,007	$	28,277,386

The fair value of contingent payments classified as a liability was estimated using the Monte Carlo simulation valuation model with Level 3 inputs. The assumptions used to estimate the fair value of contingent payments that were classified as a liability at December 31, 2019 were as follows:

Expected volatility	95.3	%
Risk-free interest rate	1.6	%
Cost of capital	30.0	%

If applicable, the Company will recognize transfers into and out of levels within the fair value hierarchy at the end of the reporting period in which the actual event or change in circumstance occurs. There were no transfers into and out of any of the levels of the fair value hierarchy during 2019 or 2018.

Assets recorded at fair value on a nonrecurring basis, such as property and equipment, intangible assets, and goodwill are recognized at fair value when they are impaired. During the years ended December 31, 2019 and 2018, the Company recognized goodwill and intangible asset impairments (Note 6) measured at fair value on a nonrecurring basis.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Employee Benefit Plans

12 Months Ended

Dec. 31, 2019

Compensation And Retirement Disclosure [Abstract]

Employee Benefit Plans

18.	Employee Benefit Plans

The Company has a 401(k)-retirement plan in which substantially all of our employees in the United States are eligible to participate in. Eligible employees may elect to contribute up to the maximum limits, as set by the Internal Revenue Service, of their eligible compensation. During 2019 and 2018, we made discretionary plan contributions of $131,412 and $139,042, respectively.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Principles of Consolidation

Use of Estimates

Comprehensive Loss

For the years presented, the total comprehensive loss includes net loss and other comprehensive loss which represents unrealized gains on investments and foreign currency translation adjustments.

Foreign Currency Translation

Segment

Investments

Intangible Assets

Impairment of Long-lived Assets and Goodwill

Fair Value Measurements

Level 1 — Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can access at the measurement date.

Level 3 — Unobservable inputs developed using estimates of assumptions developed by the Company, which reflect those that a market participant would use.

Financial Instruments

Revenue

Research and Development

Concentrations of Credit Risk

Property and Equipment, Net

Depreciation and amortization are recorded using the straight-line method over the estimated useful lives of the assets, as follows:

Asset Category		Estimated Useful Life
Computer and telecommunications		3 – 5 years
Software		3 years
Furniture, fixtures and equipment		5 years
Laboratory equipment		7 years
Leasehold improvements		Lesser of lease term or estimated useful lives

Preferred Stock

Warrants

Stock-based Compensation

Income Taxes

Net Loss per Share

Leases

The Company determines if an arrangement is a lease at inception. Operating leases are recorded as a current and long-term lease obligation, with a corresponding right of use lease assets.

Contingent Consideration

Recently Issued Accounting Pronouncements

Recently Adopted:

Pending Adoptions:

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Summary of Depreciation and Amortization Recorded using Straight-line Method over Estimated Useful Lives

Depreciation and amortization are recorded using the straight-line method over the estimated useful lives of the assets, as follows:

Asset Category		Estimated Useful Life
Computer and telecommunications		3 – 5 years
Software		3 years
Furniture, fixtures and equipment		5 years
Laboratory equipment		7 years
Leasehold improvements		Lesser of lease term or estimated useful lives

Net Loss Per Share (Tables)

12 Months Ended

Dec. 31, 2019

Earnings Per Share [Abstract]

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

	As of December 31,
	2019		2018
Common stock warrants		10,384,706		7,344,297
Common stock options		973,172		353,274
Unvested restricted stock		235,666		323,404
Other dilutive securities		28,070		—

Property and Equipment, Net (Tables)

12 Months Ended

Dec. 31, 2019

Property Plant And Equipment [Abstract]

Summary of Property and Equipment, Net

Property and equipment, net consisted of the following:

	As of December 31,
	2019			2018
Furniture, fixtures and equipment	$	121,491		$	121,491
Laboratory equipment		926,590			926,590
Computers and telecommunications		150,517			149,290
Software		25,069			25,069
Leasehold improvements		1,228,108			1,228,108
Property and equipment, at cost		2,451,775			2,450,548
Less accumulated depreciation and amortization		(1,347,567	)		(1,107,746	)
Property and equipment, net	$	1,104,208		$	1,342,802

Goodwill and Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2019

Goodwill And Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets

The Company’s intangible assets consisted of the following:

	As of December 31, 2019
	Estimated Useful Lives	Gross Carrying Value		Accumulated Amortization			Impairment			Net Book Value
Internally developed patents	6 – 10 years	$	746,323	$	(448,874	)	$	—		$	297,449
Acquired licenses	16 – 20 years		285,000		(269,221	)		—			15,779
Total intangible assets subject to amortization		$	1,031,323	$	(718,095	)	$	—		$	313,228
IPR&D assets	Indefinite		13,418,967		—			(1,000,000	)		12,418,967
Total		$	14,450,290	$	(718,095	)	$	(1,000,000	)	$	12,732,195

	As of December 31, 2018
	Estimated Useful Lives	Gross Carrying Value		Accumulated Amortization			Impairment			Net Book Value
Internally developed patents	6 – 10 years	$	718,559	$	(317,172	)	$	—		$	401,387
Acquired licenses	16 – 20 years		285,000		(253,430	)		—			31,570
Total intangible assets subject to amortization		$	1,003,559	$	(570,602	)	$	—		$	432,957
IPR&D assets	Indefinite		37,868,978		—			(24,450,011	)		13,418,967
Total		$	38,872,537	$	(570,602	)	$	(24,450,011	)	$	13,851,924

Schedule of Future Estimated Amortization Expense

As of December 31, 2019, future estimated amortization expense is as follows:

For the Year Ended December 31,
2020	$	42,275
2021		26,059
2022		26,059
2023		26,059
2024		22,153
2025 and thereafter		170,623
Total	$	313,228

Schedule of Changes in Carrying Amounts of IPR&D Assets and Goodwill

Changes in the carrying amounts of IPR&D assets and goodwill for the years ended December 31, 2019 and 2018 were:

	IPR&D			Goodwill
Balance, January 1, 2018	$	38,245,871		$	—
Additions		—			490,676
Foreign currency translation adjustments		(376,893	)		—
Impairment charges		(24,450,011	)		(490,676	)
Balance, December 31, 2018	$	13,418,967		$	—
Impairment charges		(1,000,000	)
Balance, December 31, 2019	$	12,418,967		$	—

Accrued Expenses and Other Current Liabilities (Tables)

12 Months Ended

Dec. 31, 2019

Payables And Accruals [Abstract]

Schedule of Accrued Expense and Other Current Liabilities

Accrued expense and other current liabilities consist of the following:

	As of December 31,
	2019		2018
Accrued professional services	$	429,467	$	552,619
Accrued payroll and employee benefits		1,183,130		1,257,191
Accrued interest		5,047		1,192
Lease obligation, current portion		259,449		—
Deferred rent, current portion		—		175,490
Accrued research and development		1,966,111		2,076,704
Deferred revenue		61,563		19,753
Total accrued expenses	$	3,904,767	$	4,082,949

Notes Payable and Other Liabilities (Tables)

12 Months Ended

Dec. 31, 2019

Notes Payable And Other Liabilities Disclosure [Abstract]

Summary of Current Portion of Outstanding Notes Payable

The Company’s current portion of outstanding notes payable are summarized as follows:

	As of December 31,
	2019		2018
BPI France notes, short-term portion	$	—	$	71,596
Total notes payable	$	—	$	71,596

Summary of Long-term Portion of Outstanding Notes Payable as well as Other Long-Term Liabilities

The Company’s long-term portion of outstanding notes payable as well as other long-term liabilities are summarized as follows:

	As of December 31,
	2019		2018
BPI France notes, long-term portion	$	—	$	501,174
Lease obligation, long-portion (see Note 15)		1,484,679		—
Deferred rent, long-term portion		—		1,045,807
Common stock warrant liability (see Note 12)		10,000		65,000
Economic conditional grants		250,000		100,000
Other		120,196		140,090
Total other long-term liabilities	$	1,864,875	$	1,852,071

Preferred Stock (Tables)

12 Months Ended

Dec. 31, 2019

Equity [Abstract]

Summary of Periodic Changes Fair Value of Embedded Redemption Derivative Financial Instrument

Balance, January 1, 2018	$	27,236
Changes in fair value		(27,236	)
Balance, December 31, 2018	$	—

Warrants (Tables)

12 Months Ended

Dec. 31, 2019

Summary of Common Stock Warrants Outstanding

The following common stock warrants were outstanding at December 31, 2019:

Number of

Common

Stock

Warrants

Per Share

Exercise

Price

Issuance Date

Expiration Date

Replacement warrants

155

483.00

March 3, 2012

March 3, 2022

Issued with redeemable preferred stock*

80.10

August 16, 2017

August 16, 2022

Issued with common units in Unit Offering

2,505,250

2.75

October 2, 2018

October 2, 2023

Underwriter warrant issued with public offering

196,650

6.25

October 2, 2018

September 28, 2021

Issued with common units in the Second Registered Direct Offering

4,629,630

5.40

October 10, 2018

October 10, 2023

Issued with common units in the Third Registered Direct Offering

3,052,959

3.21

March 12, 2019

March 12, 2024

Total

10,384,706

*Liability classified warrants

The following common stock warrants were outstanding at December 31, 2018:

Number of

Common

Stock

Warrants

Per Share

Exercise

Price

Issuance Date

Expiration Date

Replacement warrants

155

483.00

March 3, 2012

March 3, 2022

Issued with redeemable preferred stock*

1,612

80.10

August 16, 2017

August 16, 2022

Issued with common units in Unit Offering

2,516,250

4.18

October 2, 2018

October 2, 2023

Underwriter warrant issued with public offering

196,650

6.25

October 2, 2018

September 28, 2021

Issued with common units in the Second Registered Direct Offering

4,629,630

5.40

October 10, 2018

October 10, 2023

Total

7,344,297

*Liability classified warrants

Summary of Key Assumptions Used in Calculating Marketability Discount

This amount is considered a marketability discount calculated based on an analysis of the leak out provision provided for in the exchange agreements. The key assumptions used in calculating the marketability discount were:

Holding period, in years	0.03
Risk free rate	1.77	%
Dividend yield	0	%
Volatility	109.9	%

Summary of Income Statement Effect of Changes in Outstanding Warrants

The following is a summary of the income statement effect of changes in the Company’s outstanding warrants:

	Year Ended December 31,
	2019		2018
Changes in fair value of warrants	$	30,000	$	(9,160	)
Loss on warrants exchanged		—		(2,688,012	)
Transaction costs		—		(181,312	)
Change in fair value of warrant liability, including gain (loss) on exchange	$	30,000	$	(2,878,484	)

Summary of Warrant Activity

A summary of warrant activity during the years ended December 31, 2019 and 2018 is as follows:

	Year Ended December 31,
	2019			2018
Warrants outstanding, January 1		7,344,297			78,336
Issuances		3,052,959			7,342,530
Exercises, conversions, exchanges and repurchases		(12,550	)		(76,569	)
Warrants outstanding, December 31		10,384,706			7,344,297

Summary of Periodic Changes in Fair Value of Warrant Liability

The periodic changes in the fair value of the warrant liability is as follows:

Balance, January 1, 2018	$	3,400,869
Warrants settled upon exchange		(3,345,029	)
Changes in fair value		9,160
Balance, December 31, 2018		65,000
Warrant repurchases		(25,000	)
Changes in fair value		(30,000	)
Balance, December 31, 2019	$	10,000

Summary of Assumptions Used to Estimate Fair Value

Expected volatility	95.3	%
Risk-free interest rate	1.6	%
Cost of capital	30.0	%

Monte Carlo Simulation Model [Member]

Summary of Assumptions Used to Estimate Fair Value

	As of December 31,
	2019			2018
Expected volatility		89.87	%		93.90	%
Expected term (years)		2.63			3.60
Risk-free interest rate		1.61	%		2.48	%
Expected dividend yield		0.00	%		0.00	%

Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2019

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Summary of Fair Value of Stock Options Issued to Employees

The fair value of stock option issued to employees was estimated at the date of grant using Black-Scholes with the following weighted-average assumptions:

	For the Year Ended December 31,
	2019			2018
Expected volatility		92.68	%		92.14	%
Expected term (years)		5.89			6.07
Risk-free interest rate		2.17	%		2.86	%
Expected dividend yield		0.00	%		0.00	%

Schedule of Information Related to Stock Options Outstanding

A summary of stock option activities under the Plans is presented below:

	Number of Stock Options			Weighted- Average Exercise Price		Weighted-Average Remaining Contractual Term (Year)		Weighted- Average Intrinsic Value
Outstanding, January 1, 2019		353,274		$	10.97		6.04	$	-
Granted		725,000			2.67
Exercised		—						$	-
Forfeited or expired		(105,102	)		14.89
Outstanding, December 31, 2019		973,172		$	4.36		5.91	$	-
Exercisable, December 31, 2019		289,518		$	6.86		5.48	$	-
Expected to vest, December 31, 2019		594,779		$	3.30		6.09	$	-

Summary of Restricted Stock Activity

A summary of restricted stock activities is presented below:

	Shares			Weighted- average Grant Date Fair Value
Unvested, January 1, 2019		323,404		$	4.06
Vested		(87,738	)		4.58
Unvested, December 31, 2019		235,666		$	3.87

Schedule of Stock-based Compensation Expense

Stock-based compensation expense is classified in the accompanying consolidated statements of operations and comprehensive loss for the years ended December 31, 2019 and 2018 as follows:

	Year-Ended December 31,
	2019		2018
Research and development	$	356,718	$	319,354
General and administrative		907,513		453,894
Total	$	1,264,231	$	773,248

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2019

Income Tax Disclosure [Abstract]

Components of Net Loss Before Income Tax Benefit

The components of net loss before income tax benefit are as follows:

	Year Ended December 31,
	2019		2018
U.S. operations	$	18,562,738	$	38,979,638
Non-U.S. operations		2,015,893		6,341,308
Net loss before income tax benefit	$	20,578,631	$	45,320,946

Components of Income Tax Benefits

The components of the income tax benefits are as follows:

	Year Ended December 31,
	2019		2018
U.S. federal
Current	$	—	$	271,356
Deferred		45,465		4,309,534
US state and local
Current		—		(1,464	)
Deferred		13,035		1,570,368
Income tax benefit	$	58,500	$	6,149,794

Reconciliation Between Effect of Applying Federal Statutory Rate and Effective Income Tax Rate Used to Calculate Income Tax Benefit

Reconciliation between the effect of applying the federal statutory rate and the effective income tax rate used to calculate the Company’s income tax benefit is as follows:

	Year Ended December 31,
	2019			2018
Federal statutory rate		21.00	%		21.00	%
State income taxes, net of federal benefit		3.12			4.53
Foreign income tax rate differential		(0.01	)		(0.15	)
Stock compensation		(0.93	)		(0.16	)
Research and development tax credit		(1.51	)		(1.30	)
Acquisition costs		(0.91	)		—
Goodwill impairment		—			(0.22	)
Acquired in process research and development impairment		(7.03	)		—
Loss on warrant exchange and warrant FMV changes		0.03			(1.33	)
Permanent differences and other		(0.99	)		2.14
Change in valuation allowance		(12.49	)		(10.94	)
Effective tax rate		0.28	%		13.57	%

Components of Deferred Tax Assets and Liabilities

Significant components of the Company’s deferred tax assets and liabilities are as follows:

	December 31,
	2019			2018
Deferred tax assets:
Domestic NOLs	$	8,141,204		$	4,025,587
Foreign NOLs		5,352,556			5,303,154
Accrued expenses		208,604			162,814
Amortization		947,115			1,035,765
Deferred revenue		44,558			38,494
Stock compensation		622,789			568,165
Deferred rent		—			336,070
Lease Liability		479,940			—
Research and development carryforward		73,155			73,156
Total deferred tax assets		15,869,921			11,543,205
Deferred tax liabilities:
IPR&D assets		(2,373,304	)		(2,557,085	)
Right of Use Asset		(192,160	)		—
Depreciation		(154,678	)		(205,859	)
IRC §481(a) adjustment		—			—
Total deferred tax liabilities		(2,720,142	)		(2,762,944	)
Deferred tax assets, net		13,149,779			8,780,261
Valuation allowance		(13,149,779	)		(8,838,761	)
Total deferred tax liabilities net	$	—		$	(58,500	)

Lease Obligations (Tables)

12 Months Ended

Dec. 31, 2019

Leases [Abstract]

Summary of Supplemental other Information Related to Operating Leases Balance Sheet

Supplemental other information related to the operating leases balance sheet information is as follows:

	December 31, 2019
Operating lease obligations	$	1,744,128
Right of use asset	$	698,321
Weighted-average remaining lease term		5.33
Weighted-average discount rate		8.0	%

Summary of Maturities of Lease Liabilities

Maturities of lease liabilities are as follows:

Year ending December 31,
2020	$	387,079
2021		393,542
2022		400,198
2023		407,054
2024		414,117
2025 and thereafter		138,831
Total lease payments		2,140,821
Less imputed interest		(396,693	)
Total	$	1,744,128

Fair Value Measurement (Tables)

12 Months Ended

Dec. 31, 2019

Fair Value Disclosures [Abstract]

Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis

The Company’s assets and liabilities measured at fair value on a recurring basis at December 31, 2019 consisted of the following:

	Fair Value Measurement at December 31, 2019
	Total		Level 1		Level 2		Level 3
Recurring fair value measurements
Cash equivalents - money market funds	$	8,034,640	$	8,034,640	$	—	$	—
Short-term investments		28,277,386		—		28,277,386		—
Contingent consideration		2,750,000		—		—		2,750,000
Warrant liability		10,000		—		—		10,000

The Company’s assets and liabilities measured at fair value on a recurring basis at December 31, 2018 consisted of the following:

	Fair Value Measurement at December 31, 2018
	Total		Level 1		Level 2		Level 3
Recurring fair value measurements
Cash equivalents — money market fund	$	29,375,509	$	29,375,509	$	—	$	—
Warrant liability		65,000		—		—		65,000

Schedule of Short Term Investments

Short-term investments had quoted prices at December 31, 2019 as shown below:

	As of December 31, 2019
	Amortized Cost		Unrealized Gain		Market Value

United States treasury securities	$	3,394,579	$	3,228	$	3,397,807
Corporate debt securities		24,862,800		16,779		24,879,579
Total	$	28,257,379	$	20,007	$	28,277,386

Summary of Assumptions Used to Estimate Fair Value

Expected volatility	95.3	%
Risk-free interest rate	1.6	%
Cost of capital	30.0	%

- Definition

Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.

+ References + Details

Summary of Significant Accounting Policies - Additional Information (Detail)	3 Months Ended	12 Months Ended
	Dec. 31, 2018 USD ($)	Dec. 31, 2019 USD ($) Segment	Dec. 31, 2018 USD ($)	Jan. 01, 2019 USD ($)
Significant Accounting Policies [Line Items]
Number of operating segments \| Segment		1
Goodwill impairment charges			$ 490,676
Goodwill	$ 0	$ 0	0
Fair value transfers, Level 1 to Level 2 assets	0	0	0
Fair value transfers, Level 2 to Level 1 assets	0	0	0
Fair value transfers, Level 1 to Level 2 liabilities	0	0	0
Fair value transfers, Level 2 to Level 1 liabilities	0	0	0
Restricted cash	634,416	34,174	$ 634,416
Restricted cash released		$ 600,000
ASU 2016-02 [Member]
Significant Accounting Policies [Line Items]
Increase in total assets on the consolidated balance sheet due to adoption of ASU 2016-02				$ 756,347
Increase in total liabilities on the consolidated balance sheet due to adoption of ASU 2016-02				$ 756,347
Revenue from Rights Concentration Risk [Member] \| Research Grants and Contracts [Member]
Significant Accounting Policies [Line Items]
Percentage of concentration of credit risk		100.00%	100.00%
Revenue from Rights Concentration Risk [Member] \| Accounts Receivable [Member]
Significant Accounting Policies [Line Items]
Percentage of concentration of credit risk		100.00%	100.00%
Money Market Funds [Member]
Significant Accounting Policies [Line Items]
Restricted cash	634,416	$ 34,174	$ 634,416
IPR&D [Member]
Significant Accounting Policies [Line Items]
Impairments	$ 24,450,011	$ 1,000,000	$ 24,450,011
Minimum [Member]
Significant Accounting Policies [Line Items]
Intangible assets amortization period		6 years
Maximum [Member]
Significant Accounting Policies [Line Items]
Intangible assets amortization period		20 years

Summary of Significant Accounting Policies - Summary of Depreciation and Amortization Recorded using Straight-line Method over Estimated Useful Lives (Detail)	12 Months Ended
	Dec. 31, 2019
Computers and Telecommunications [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of assets	3 years
Computers and Telecommunications [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of assets	5 years
Software [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of assets	3 years
Furniture, Fixtures and Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of assets	5 years
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of assets	7 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of assets	Lesser of lease term or estimated useful lives

Acquisitions - Additional Information (Detail) - USD ($)		12 Months Ended
	Jul. 12, 2019	Dec. 31, 2019
Business Acquisition [Line Items]
In-process research and development expenses		$ 6,541,485
Spitfire Pharma, Inc. [Member]
Business Acquisition [Line Items]
Agreement date	Jul. 08, 2019
Unregistered shares of common stock	1,887,250
Up-front consideration	$ 5,000,000	4,337,574
Number of consecutive trading days	20 days
Upfront consideration release at 6 months	33.30%
Upfront consideration release at 12 months	33.30%
Upfront consideration release at 18 months	33.30%
Stock price	$ 2.45
Estimated discount for lack of marketability	$ 832,277
In-process research and development expenses		2,750,000
Transaction cost recorded within research and development expense		$ 680,090
Spitfire Pharma, Inc. [Member] \| Investigational New Drug Application Milestone [Member]
Business Acquisition [Line Items]
Future contingent payments	$ 5,000,000
Future contingent payment term	60 days
Spitfire Pharma, Inc. [Member] \| Investigational New Drug Application and Regulatory Milestones [Member]
Business Acquisition [Line Items]
Future contingent payments	$ 3,000,000
Future contingent payment term	60 days
Spitfire Pharma, Inc. [Member] \| Sales Milestones [Member]
Business Acquisition [Line Items]
Future contingent payments	$ 80,000,000
License agreement term	10 years
Spitfire Pharma, Inc. [Member] \| Regulatory Milestones [Member]
Business Acquisition [Line Items]
Upfront consideration release at 6 months	50.00%
Upfront consideration release at 3 months	50.00%
Spitfire Pharma, Inc. [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Future contingent payments	$ 88,000,000

Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail) - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	10,384,706	7,344,297
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	973,172	353,274
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	235,666	323,404
Other Dilutive Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	28,070

Property and Equipment, Net - Summary of Property and Equipment, Net (Detail) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Property and equipment, at cost	$ 2,451,775	$ 2,450,548
Less accumulated depreciation and amortization	(1,347,567)	(1,107,746)
Property and equipment, net	1,104,208	1,342,802
Furniture, Fixtures and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, at cost	121,491	121,491
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, at cost	926,590	926,590
Computers and Telecommunications [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, at cost	150,517	149,290
Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, at cost	25,069	25,069
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, at cost	$ 1,228,108	$ 1,228,108

Property and Equipment, Net - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Property Plant And Equipment [Abstract]
Depreciation	$ 239,821	$ 218,717

Goodwill and Intangible Assets - Schedule of Intangible Assets (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Schedule Of Intangible Assets [Line Items]
Intangible assets subject to amortization, Gross Carrying Value	$ 1,031,323	$ 1,003,559
Intangible assets subject to amortization, Accumulated Amortization	(718,095)	(570,602)
Intangible assets subject to amortization, Net Book Value	313,228	432,957
Total intangible assets, Gross Carrying Value	14,450,290	38,872,537
Intangible Assets, Impairment	(1,000,000)	(24,450,011)
Total intangible assets, Net Book Value	12,732,195	13,851,924
IPR&D [Member]
Schedule Of Intangible Assets [Line Items]
Total intangible assets, Gross Carrying Value	13,418,967	37,868,978
Total intangible assets, Impairment	(1,000,000)	(24,450,011)
Total intangible assets, Net Book Value	12,418,967	13,418,967
Internally Developed Patents [Member]
Schedule Of Intangible Assets [Line Items]
Intangible assets subject to amortization, Gross Carrying Value	746,323	718,559
Intangible assets subject to amortization, Accumulated Amortization	(448,874)	(317,172)
Intangible assets subject to amortization, Net Book Value	$ 297,449	$ 401,387
Internally Developed Patents [Member] \| Minimum [Member]
Schedule Of Intangible Assets [Line Items]
Estimated Useful Lives	6 years	6 years
Internally Developed Patents [Member] \| Maximum [Member]
Schedule Of Intangible Assets [Line Items]
Estimated Useful Lives	10 years	10 years
Acquired Licenses [Member]
Schedule Of Intangible Assets [Line Items]
Intangible assets subject to amortization, Gross Carrying Value	$ 285,000	$ 285,000
Intangible assets subject to amortization, Accumulated Amortization	(269,221)	(253,430)
Intangible assets subject to amortization, Net Book Value	$ 15,779	$ 31,570
Acquired Licenses [Member] \| Minimum [Member]
Schedule Of Intangible Assets [Line Items]
Estimated Useful Lives	16 years	16 years
Acquired Licenses [Member] \| Maximum [Member]
Schedule Of Intangible Assets [Line Items]
Estimated Useful Lives	20 years	20 years

Goodwill and Intangible Assets - Additional Information (Detail)	3 Months Ended	12 Months Ended
	Dec. 31, 2018 USD ($) Asset	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($) Asset	Dec. 31, 2017 USD ($)
Schedule Of Intangible Assets [Line Items]
Carrying value of assets	$ 38,872,537	$ 14,450,290	$ 38,872,537
Impairment charges		1,000,000	24,940,687
Goodwill impairment charges			$ 490,676
IPR&D [Member]
Schedule Of Intangible Assets [Line Items]
Number of assets \| Asset	3		3
Intangible assets, amount	$ 13,418,967	12,418,967	$ 13,418,967	$ 38,245,871
Impairment charge	24,450,011	$ 1,000,000	24,450,011
IPR&D [Member] \| Oncosyn Cancer Immunotherapy [Member]
Schedule Of Intangible Assets [Line Items]
Intangible assets, amount	$ 3,061,011		$ 3,061,011
IPR&D [Member] \| HepTcell and SparVax-L [Member]
Schedule Of Intangible Assets [Line Items]
Number of assets \| Asset	2		2
IPR&D [Member] \| SparVax-L [Member]
Schedule Of Intangible Assets [Line Items]
Fair value of intangible assets	$ 1,000,000		$ 1,000,000
Carrying value of assets	22,389,000		$ 22,389,000
Impairment charge	$ 21,389,000
Minimum [Member] \| IPR&D [Member]
Schedule Of Intangible Assets [Line Items]
Estimated Useful Lives		15 years
Maximum [Member] \| IPR&D [Member]
Schedule Of Intangible Assets [Line Items]
Estimated Useful Lives		18 years
Maximum [Member] \| IPR&D [Member] \| HepTcell [Member]
Schedule Of Intangible Assets [Line Items]
Percent of fair value of reporting unit excess of carrying value	10.00%		10.00%
Research and Development [Member]
Schedule Of Intangible Assets [Line Items]
Amortization expense of intangible assets		$ 147,500	$ 83,652

Goodwill and Intangible Assets - Schedule of Future Estimated Amortization Expense (Detail) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Goodwill And Intangible Assets Disclosure [Abstract]
2020	$ 42,275
2021	26,059
2022	26,059
2023	26,059
2024	22,153
2025 and thereafter	170,623
Intangible assets subject to amortization, Net Book Value	$ 313,228	$ 432,957

Goodwill and Intangible Assets - Schedule of Changes in Carrying Amounts of IPR&D Assets and Goodwill (Detail) - USD ($)	3 Months Ended	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Indefinite Lived Intangible Assets By Major Class [Line Items]
Goodwill Balance, beginning of period		$ 0
Goodwill, Additions from the mergers			$ 490,676
Goodwill, Impairment charges			(490,676)
Goodwill Balance, end of period	$ 0	0	0
IPR&D [Member]
Indefinite Lived Intangible Assets By Major Class [Line Items]
IPR&D Balance, beginning of period		13,418,967	38,245,871
IPR&D, Foreign currency translation adjustments			(376,893)
IPR&D, Impairment charges	(24,450,011)	(1,000,000)	(24,450,011)
IPR&D Balance, end of period	$ 13,418,967	$ 12,418,967	$ 13,418,967

Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expense and Other Current Liabilities (Detail) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Accrued Liabilities And Other Liabilities [Abstract]
Accrued professional services	$ 429,467	$ 552,619
Accrued payroll and employee benefits	1,183,130	1,257,191
Accrued interest	5,047	1,192
Lease obligation, current portion	259,449
Deferred rent, current portion		175,490
Accrued research and development	1,966,111	2,076,704
Deferred revenue	61,563	19,753
Total accrued expenses	$ 3,904,767	$ 4,082,949

Licenses - Additional Information (Detail) - USD ($)	12 Months Ended
Licenses - Additional Information (Detail) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
University of Alabama at Birmingham Research Foundation [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Annual license fee	$ 20,000
Type of Cost, Good or Service [Extensible List]	us-gaap:LicenseMember	us-gaap:LicenseMember
License fee costs	$ 20,000	$ 20,000
Janssen Vaccines and Prevention BV [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Annual license fee	$ 100,000
Type of Cost, Good or Service [Extensible List]	us-gaap:LicenseMember	us-gaap:LicenseMember
License fee costs	$ 111,499	$ 177,625
License agreement expiration period from the date of first commercial sale of relevant product	15 years
Auburn University [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Annual license fee	$ 5,000
Type of Cost, Good or Service [Extensible List]	us-gaap:LicenseMember	us-gaap:LicenseMember
License fee costs	$ 5,000	$ 5,000
Patent expiration date	Aug. 15, 2025
Upfront fee	$ 1,000

Notes Payable and Other Liabilities - Summary of Current Portion of Outstanding Notes Payable (Detail)	Dec. 31, 2018 USD ($)
Debt Instrument [Line Items]
Total notes payable	$ 71,596
BPI France Notes [Member]
Debt Instrument [Line Items]
Total notes payable	$ 71,596

Notes Payable and Other Liabilities - Summary of Long-term Portion of Outstanding Notes Payable as well as Other Long-Term Liabilities (Detail) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Lease obligation, long-portion (see Note 15)	$ 1,484,679
Deferred rent, long-term portion		$ 1,045,807
Common stock warrant liability (see Note 12)	10,000	65,000
Economic conditional grants	250,000	100,000
Other	120,196	140,090
Total other long-term liabilities	$ 1,864,875	1,852,071
BPI France Notes [Member]
Debt Instrument [Line Items]
BPI France notes, long-term portion		$ 501,174

Notes Payable and Other Liabilities - Additional Information (Detail)		12 Months Ended
	Jun. 05, 2019 EUR (€)	Dec. 31, 2019 USD ($) FundingArrangement Grant d $ / shares shares	Dec. 31, 2019 EUR (€) FundingArrangement Grant d	Dec. 31, 2018 USD ($)	Dec. 31, 2019 EUR (€) shares	Jun. 29, 2018 USD ($) shares
Debt Instrument [Line Items]
Revenue		$ 5,801,401		$ 10,331,168
Repayments of notes payable		292,002		1,549,702
Economic conditional incentive grants		250,000		100,000
Interest expense		2,244		297,090
Convertible Debt [Member]
Debt Instrument [Line Items]
Convertible note unamortized discount		180,611
Debt issuance costs		58,172
Interest expense				$ 293,009
Additional interest earned		54,226
First Exchange Warrants [Member]
Debt Instrument [Line Items]
Convertible notes principal balance		$ 1,500,000				$ 1,500,000
Shares of common stock called by warrants \| shares		73,530			73,530	53,125
Convertible debt, interest rate in event of default		112.00%	112.00%
Conversion price per share \| $ / shares		$ 20.40
Weighted average prices of common stock		75.00%	75.00%
Weighted average price per share of common stock \| $ / shares		$ 4.50
Number of trading days \| d		20	20
Montgomery County [Member]
Debt Instrument [Line Items]
Expiration date of economic conditional incentive grant		Feb. 28, 2028	Feb. 28, 2028
Accrued interest rate on grant		3.00%	3.00%
State of Maryland [Member]
Debt Instrument [Line Items]
Expiration date of economic conditional incentive grant		Dec. 31, 2029	Dec. 31, 2029
Economic incentive grant term		10 years	10 years
Accrued interest rate on grant		3.00%	3.00%
Montgomery County and State of Maryland [Member]
Debt Instrument [Line Items]
Economic conditional incentive grants		$ 250,000
Number of economic conditional incentive grants \| Grant		2	2
Interest expense		$ 5,042
BPI France Notes [Member]
Debt Instrument [Line Items]
Number of non-interest bearing research and development funding arrangements \| FundingArrangement		2	2
Percentage of fund to be withdrawn upon signing of arrangements		50.00%	50.00%
Additional percentage of fund to be withdrawn, contingent upon financial audit and technical progress report		30.00%	30.00%
Research and development funding arrangements extended period		2 years	2 years
Total long-term debt \| €					€ 500,000
Revenue		$ 265,540	€ 238,229
Paid in excess of allowable funding amount \| €	€ 102,951
Repayments of notes payable		292,002
BPI France Notes [Member] \| Research Funding First Arrangement [Member]
Debt Instrument [Line Items]
Debt instrument, face amount \| €					750,000
BPI France Notes [Member] \| Research Funding Second Arrangement [Member]
Debt Instrument [Line Items]
Debt instrument, face amount \| €					€ 250,000
BPI France Notes [Member] \| Grant [Member]
Debt Instrument [Line Items]
Long-term debt converted amount		$ 265,540	€ 238,229

Preferred Stock - Additional Information (Detail) - USD ($)			12 Months Ended
	Jul. 11, 2018	Aug. 16, 2017	Dec. 31, 2018	Dec. 31, 2019	Jun. 30, 2018
Temporary Equity [Line Items]
Deemed dividend			$ 56,792
Redeemable convertible preferred shares outstanding			0	0
Common Stock [Member]
Temporary Equity [Line Items]
Conversion of Series B redeemable convertible preferred stock into common stock, shares			502,078
Second Warrants Exchange [Member]
Temporary Equity [Line Items]
Stock issued for exchange of warrants, shares	22,523
Number of shares issued	32,124
Series B Redeemable Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Convertible preferred shares, shares issued		15,656
Convertible preferred shares, par value		$ 0.0001
Stock issued for exchange of warrants		$ 14,716,370
Issuance costs incurred		$ 1,697,800
Redeemable preferred stock redemption date		Aug. 16, 2018
Percentage of common stock in reserve for issue on conversion		150.00%
Conversion of redeemable preferred stock into common stock, shares			9,813
Series B Redeemable Convertible Preferred Stock [Member] \| Level 3 [Member]
Temporary Equity [Line Items]
Beneficial conversion feature		$ 1,506,196	$ 1,338,840
Series B Preferred Stock [Member]
Temporary Equity [Line Items]
Face value of preferred stock					$ 2,364,044
Face value of preferred stock, shares					2,364
Series B Preferred Stock [Member] \| Second Warrants Exchange [Member]
Temporary Equity [Line Items]
Number of shares issued	32,124
Proceeds from issuance of warrants	$ 22,241
Deemed contribution			$ 111,553
Maximum [Member] \| Series B Redeemable Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Stock issued for exchange of warrants, shares		78,181

Preferred Stock - Summary of Periodic Changes Fair Value of Embedded Redemption Derivative Financial Instrument (Detail)	12 Months Ended
	Dec. 31, 2018 USD ($)
Fair Value Assets And Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Abstract]
Balance, beginning of period	$ 27,236
Changes in fair value	$ (27,236)

Common Stock - Additional Information (Detail) - USD ($)						12 Months Ended
	Jul. 12, 2019	Mar. 12, 2019	Oct. 10, 2018	Oct. 02, 2018	Sep. 26, 2018	Dec. 31, 2018	Dec. 31, 2019
Changes In Equity And Comprehensive Income Line Items [Line Items]
Net proceeds from offering						$ 4,334,816
Deemed dividend						56,792
Spitfire Pharma, Inc. [Member]
Changes In Equity And Comprehensive Income Line Items [Line Items]
Unregistered shares of common stock	1,887,250
First Registered Direct Offering [Member]
Changes In Equity And Comprehensive Income Line Items [Line Items]
Shares of common stock issued					286,633
Purchase price per share					$ 17.02
Net proceeds from offering					$ 4,334,816
Placement agent fees and offering expenses					$ 543,677
Unit Offering [Member]
Changes In Equity And Comprehensive Income Line Items [Line Items]
Net proceeds from offering				$ 10,667,506
Common units outstanding				2,400,000
Sale of transaction date				Oct. 02, 2018
Common units issued				2,400,000
Unit Offering [Member] \| Common Units
Changes In Equity And Comprehensive Income Line Items [Line Items]
Public offering price per share				$ 5.00
Per share exercise price				$ 6.00
Warrant expiration period				5 years
Unit Offering [Member] \| Common Units [Member]
Changes In Equity And Comprehensive Income Line Items [Line Items]
Public offering price per share				$ 4.99
Per share exercise price				0.01
Per share exercise price				$ 6.00
Second Registered Direct Offering [Member]
Changes In Equity And Comprehensive Income Line Items [Line Items]
Net proceeds from offering			$ 22,400,673
Common units outstanding			4,629,630
Sale of transaction date			Oct. 10, 2018
Common units issued							4,629,630
Deemed dividend						$ 780,038
Second Registered Direct Offering [Member] \| Maximum [Member]
Changes In Equity And Comprehensive Income Line Items [Line Items]
Per share exercise price			$ 6.00
Second Registered Direct Offering [Member] \| Minimum [Member]
Changes In Equity And Comprehensive Income Line Items [Line Items]
Per share exercise price			4.1798
Second Registered Direct Offering [Member] \| Common Units
Changes In Equity And Comprehensive Income Line Items [Line Items]
Public offering price per share			5.40
Per share exercise price			$ 5.40
Warrant expiration period			5 years
Second Registered Direct Offering [Member] \| Common Units [Member]
Changes In Equity And Comprehensive Income Line Items [Line Items]
Public offering price per share			$ 5.39
Per share exercise price			5.40
Per share exercise price			$ 0.01
Third Registered Direct Offering [Member]
Changes In Equity And Comprehensive Income Line Items [Line Items]
Net proceeds from offering		$ 12,668,784
Common units outstanding		4,361,370
Sale of transaction date		Mar. 12, 2019
Warrant expiration period		5 years
Deemed dividend							$ 452,925
Third Registered Direct Offering [Member] \| Maximum [Member]
Changes In Equity And Comprehensive Income Line Items [Line Items]
Per share exercise price		$ 4.1798
Third Registered Direct Offering [Member] \| Minimum [Member]
Changes In Equity And Comprehensive Income Line Items [Line Items]
Per share exercise price		2.7568
Third Registered Direct Offering [Member] \| Common Units
Changes In Equity And Comprehensive Income Line Items [Line Items]
Public offering price per share		3.21
Per share exercise price		$ 3.21
Shares of common stock called by warrants		0.70
Third Registered Direct Offering [Member] \| Common Units [Member]
Changes In Equity And Comprehensive Income Line Items [Line Items]
Public offering price per share		$ 3.20
Per share exercise price		0.01
Per share exercise price		$ 3.21
Shares of common stock called by warrants		0.70

Warrants - Summary of Common Stock Warrants Outstanding (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Class of Warrant or Right [Line Items]
Number of Common Stock Warrants	10,384,706	7,344,297	78,336
Replacement Warrants [Member]
Class of Warrant or Right [Line Items]
Number of Common Stock Warrants	155	155
Per Share Exercise Price	$ 483.00	$ 483.00
Issuance Date	Mar. 03, 2012	Mar. 03, 2012
Expiration Date	Mar. 03, 2022	Mar. 03, 2022
Warrants Issued with Redeemable Preferred [Member]
Class of Warrant or Right [Line Items]
Number of Common Stock Warrants	62	1,612
Per Share Exercise Price	$ 80.10	$ 80.10
Issuance Date	Aug. 16, 2017	Aug. 16, 2017
Expiration Date	Aug. 16, 2022	Aug. 16, 2022
Warrants Issued with Common Units in Unit Offering [Member]
Class of Warrant or Right [Line Items]
Number of Common Stock Warrants	2,505,250	2,516,250
Per Share Exercise Price	$ 2.75	$ 4.18
Issuance Date	Oct. 02, 2018	Oct. 02, 2018
Expiration Date	Oct. 02, 2023	Oct. 02, 2023
Underwriter Warrant Issued with Public Offering [Member]
Class of Warrant or Right [Line Items]
Number of Common Stock Warrants	196,650	196,650
Per Share Exercise Price	$ 6.25	$ 6.25
Issuance Date	Oct. 02, 2018	Oct. 02, 2018
Expiration Date	Sep. 28, 2021	Sep. 28, 2021
Issued With Common Units in the Second Registered Direct Offering [Member]
Class of Warrant or Right [Line Items]
Number of Common Stock Warrants	4,629,630	4,629,630
Per Share Exercise Price	$ 5.40	$ 5.40
Issuance Date	Oct. 10, 2018	Oct. 10, 2018
Expiration Date	Oct. 10, 2023	Oct. 10, 2023
Issued With Common Units in the Third Registered Direct Offering [Member]
Class of Warrant or Right [Line Items]
Number of Common Stock Warrants	3,052,959
Per Share Exercise Price	$ 3.21
Issuance Date	Mar. 12, 2019
Expiration Date	Mar. 12, 2024

Warrants - Additional Information (Detail)				1 Months Ended			6 Months Ended	12 Months Ended
Warrants - Additional Information (Detail)	Sep. 07, 2018 shares	Jul. 11, 2018 USD ($) shares	Jun. 29, 2018 USD ($) $ / shares shares	Mar. 31, 2018 USD ($)	Aug. 31, 2017 shares	May 31, 2017 shares	Jun. 29, 2018 USD ($) $ / shares shares	Dec. 31, 2019 USD ($) $ / shares shares	Dec. 31, 2018 USD ($) $ / shares shares	Jun. 30, 2018 USD ($)	Dec. 31, 2017 shares
Class of Warrant or Right [Line Items]
Replacement warrants issued in connection with the Mergers						155
Issuances					78,181			3,052,959	7,342,530
Conversion of warrants into common stock and cash								1,550	76,569
Warrants outstanding								10,384,706	7,344,297		78,336
Stock price per share \| $ / shares								$ 0.0001	$ 0.0001
Cash proceeds from common stock \| $									$ 4,334,816
Gain on exchange of warrants \| $								$ 779,923
Exchange consideration discounted percentage							0.05
Series B Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Face value of preferred stock \| $										$ 2,364,044
First Exchange Warrants [Member]
Class of Warrant or Right [Line Items]
Stock issued for exchange of warrants, shares			53,125				53,125	73,530
Issuance of common stock for the exchange of warrants			167,700
Stock price per share \| $ / shares			$ 12.60				$ 12.60
Convertible notes principal balance \| $			$ 1,500,000				$ 1,500,000	$ 1,500,000
Cash proceeds from common stock \| $			$ 1,100,000
Proceeds from exchange of warrants \| $								4,727,000
Converted value in excess of principal \| $				$ 3,467,935
Gain on exchange of warrants \| $								(3,593,082)
Transaction costs \| $								125,147
First Exchange Warrants [Member] \| Series B Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Face value of preferred stock \| $								$ 2,364,044
Second Warrants Exchange [Member]
Class of Warrant or Right [Line Items]
Stock issued for exchange of warrants, shares		22,523
Stock price per share \| $ / shares								$ 8.64
Number of shares issued		32,124
Additional number of shares issued		145,038
Second Warrants Exchange [Member] \| Series B Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Number of shares issued		32,124
Proceeds from issuance of warrants \| $		$ 22,241
Third Warrants Exchange [Member]
Class of Warrant or Right [Line Items]
Stock issued for exchange of warrants, shares	921
Stock price per share \| $ / shares								$ 8.85
Number of shares issued	5,929
Warrants Issued with Redeemable Preferred [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding								62	1,612

Warrants - Summary of Key Assumptions Used in Calculating Marketability Discount (Detail)	Dec. 31, 2018 yr
Expected Term (Years) [Member]
Class of Warrant or Right [Line Items]
Measurement input	0.03
Risk-free Interest Rate [Member]
Class of Warrant or Right [Line Items]
Measurement input	1.77
Dividend Yield [Member]
Class of Warrant or Right [Line Items]
Measurement input	0
Expected Volatility [Member]
Class of Warrant or Right [Line Items]
Measurement input	109.9

Warrants - Summary of Income Statement Effect of Changes in Outstanding Warrants (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Class of Warrant or Right [Line Items]
Changes in fair value of warrants	$ 30,000	$ (2,878,484)
Common Stock Warrants [Member]
Class of Warrant or Right [Line Items]
Changes in fair value of warrants	30,000	(9,160)
Loss on warrants exchanged		(2,688,012)
Transaction costs		(181,312)
Change in fair value of warrant liability, including gain (loss) on exchange	$ 30,000	$ (2,878,484)

Warrants - Summary of Warrant Activity (Detail) - shares	1 Months Ended	12 Months Ended
	Aug. 31, 2017	Dec. 31, 2019	Dec. 31, 2018
Equity [Abstract]
Warrants outstanding, January 1		7,344,297	78,336
Issuances	78,181	3,052,959	7,342,530
Exercises, conversions, exchanges and repurchases		(12,550)	(76,569)
Warrants outstanding, December 31		10,384,706	7,344,297

Warrants - Summary of Periodic Changes in Fair Value of Warrant Liability (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Warrant repurchases	$ (25,000)	$ (1,100,000)
Level 3 [Member] \| Common Stock Warrants [Member]
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Balance, January 1, 2018	65,000	3,400,869
Warrants settled upon exchange		(3,345,029)
Warrant repurchases	(25,000)
Changes in fair value	(30,000)	9,160
Balance, December 31, 2018	$ 10,000	$ 65,000

Warrants - Summary of Assumptions Used to Estimate Fair Value of Warrants (Detail) - Common Stock Warrants [Member]	Dec. 31, 2019	Dec. 31, 2018
Expected Volatility [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Fair value of warrants, measurement input	89.87	93.90
Expected Term (Years) [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Fair value of warrants, measurement input, expected term (years)	2 years 7 months 17 days	3 years 7 months 6 days
Risk-free Interest Rate [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Fair value of warrants, measurement input	1.61	2.48
Expected Dividend Yield [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Fair value of warrants, measurement input	0.00	0.00

Stock-Based Compensation - Additional Information (Detail) - USD ($)		1 Months Ended		12 Months Ended
	Mar. 29, 2019	Nov. 30, 2018	Oct. 31, 2016	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2020	Nov. 29, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Stock Options, Granted				725,000
Stock-based compensation				$ 1,264,231	$ 773,248
Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average grant date fair value of stock options granted				$ 2.67	$ 4.63
Unrecognized compensation cost, stock options				$ 1,375,808
Unrecognized stock-based compensation expense, period for recognition				3 years 2 months 19 days
Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock-based compensation expense, period for recognition				2 years 11 months 1 day
Restricted stock authorized and granted			2,651
Restricted stock authorized and granted, value			$ 1,067
Weighted average grant date fair value of restricted stock award			$ 310.80
Restricted stock vesting period			4 years
Share-based compensation arrangement by share-based payment award, award vesting rights, percentage			50.00%
Number of restricted shares vested				87,738
Unrecognized compensation expense				$ 843,770
Restricted Stock [Member] \| Forecast [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Remaining shares to be vested						213
Restricted Stock [Member] \| October 2016 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value of restricted shares that vested				648
Restricted Stock [Member] \| November 30, 2018 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value of restricted shares that vested				$ 159,032
Number of restricted shares vested				87,454
Executive Officer [Member] \| Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock authorized and granted		322,907
Weighted average grant date fair value of restricted stock award		$ 3.59
Restricted stock vesting period		4 years
Share-based compensation arrangement by share-based payment award, shares vesting date		Dec. 01, 2022
Executive Officer [Member] \| Restricted Stock [Member] \| One Year Anniversary [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, award vesting rights, percentage		25.00%
Executive Officer [Member] \| Restricted Stock [Member] \| 36 Substantially Equal Monthly Installments
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, award vesting rights, percentage		75.00%
Common Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Stock Options, Granted				725,000
2001 Employee Stock Option Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Stock Options, Granted				0
2007 Long Term Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Stock Options, Granted				0
2017 Omnibus Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares reserved for future issuance, description				The aggregate share reserve will be increased on January 1 of each year commencing in 2018 and ending on and including January 1, 2027 up to an amount equal to the lowest of (i) 4% of the total number of shares of common stock outstanding on a fully diluted basis as of December 31 of the immediately preceding calendar year, and (ii) such number of shares of common stock, if any, determined by the Company’s board of directors.
Percentage of additional shares from common stock available for stock-based compensation				4.00%
2017 Omnibus Incentive Plan [Member] \| Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance				1,500,000
2017 Omnibus Incentive Plan [Member] \| Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance				5,000,000
2017 Omnibus Incentive Plan [Member] \| Common Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance				83,373
2017 Omnibus Incentive Plan [Member] \| Common Stock [Member] \| Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock granted, shares				800,000
Stock granted value				$ 5,000,000
2017 Omnibus Incentive Plan [Member] \| Common Stock [Member] \| Maximum [Member] \| Director [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock granted, shares				500,000
2018 Inducement Grant Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance							2,000,000
2018 Inducement Grant Plan [Member] \| Common Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance				1,491,582
2019 Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	403,500
Percent of payroll deductions	10.00%
Percentage of discount from fair market value of common stock on first or last trading day of offering period	85.00%
Stock-based compensation				$ 21,608

Stock-Based Compensation - Summary of Fair Value of Stock Options Issued to Employees (Detail)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Expected volatility	92.68%	92.14%
Expected term (years)	5 years 10 months 20 days	6 years 25 days
Risk-free interest rate	2.17%	2.86%
Expected dividend yield	0.00%	0.00%

Stock-Based Compensation - Schedule of Information Related to Stock Options Outstanding (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Stock Options, Outstanding	353,274
Number of Stock Options, Granted	725,000
Number of Stock Options, Forfeited or expired	(105,102)
Number of Stock Options, Outstanding	973,172	353,274
Number of Stock Options, Exercisable	289,518
Number of Stock Options, Expected to vest	594,779
Weighted-average Exercise Price, Outstanding	$ 10.97
Weighted-average Exercise Price, Granted	2.67
Weighted-average Exercise Price, Forfeited or expired	14.89
Weighted-average Exercise Price, Outstanding	4.36	$ 10.97
Weighted-average Exercise Price, Exercisable	6.86
Weighted-average Exercise Price, Expected to vest	$ 3.30
Weighted-average Remaining Contractual Term, Outstanding	5 years 10 months 28 days	6 years 14 days
Weighted-average Remaining Contractual Term, Exercisable	5 years 5 months 23 days
Weighted-average Remaining Contractual Term, Expected to vest	6 years 1 month 2 days

Stock-Based Compensation - Summary of Restricted Stock Activity (Detail) - Restricted Stock [Member]	12 Months Ended
	Dec. 31, 2019 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unvested Shares, Beginning balance \| shares	323,404
Vested Shares \| shares	(87,738)
Unvested Shares, Ending balance \| shares	235,666
Weighted-average Grant Date Fair Value Unvested, beginning balance \| $ / shares	$ 4.06
Weighted-average Grant Date Fair Value Vested \| $ / shares	4.58
Weighted-average Grant Date Fair Value Unvested, Ending balance \| $ / shares	$ 3.87

Stock-Based Compensation - Schedule of Stock-based Compensation Expense (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock based compensation expense	$ 1,264,231	$ 773,248
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock based compensation expense	356,718	319,354
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock based compensation expense	$ 907,513	$ 453,894

Income Taxes - Components of Net Loss Before Income Tax Benefit (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
U.S. operations	$ 18,562,738	$ 38,979,638
Non-U.S. operations	2,015,893	6,341,308
Net loss before income tax benefit	$ 20,578,631	$ 45,320,946

Income Taxes - Components of Income Tax Benefits (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
U.S. federal
Current		$ 271,356
Deferred	$ 45,465	4,309,534
US state and local
Current		(1,464)
Deferred	13,035	1,570,368
Income tax benefit	$ 58,500	$ 6,149,794

Income Taxes - Reconciliation Between Effect of Applying Federal Statutory Rate and Effective Income Tax Rate Used to Calculate Income Tax Benefit (Detail)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Corporate federal income tax rate	21.00%	21.00%
State income taxes, net of federal benefit	3.12%	4.53%
Foreign income tax rate differential	(0.01%)	(0.15%)
Stock compensation	(0.93%)	(0.16%)
Research and development tax credit	(1.51%)	(1.30%)
Acquisition costs	(0.91%)
Goodwill impairment		(0.22%)
Acquired in process research and development impairment	(7.03%)
Loss on warrant exchange and warrant FMV changes	0.03%	(1.33%)
Permanent differences and other	(0.99%)	2.14%
Change in valuation allowance	(12.49%)	(10.94%)
Effective tax rate	0.28%	13.57%

Income Taxes - Components of Deferred Tax Assets and Liabilities (Detail) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Deferred tax assets:
Domestic NOLs	$ 8,141,204	$ 4,025,587
Foreign NOLs	5,352,556	5,303,154
Accrued expenses	208,604	162,814
Amortization	947,115	1,035,765
Deferred revenue	44,558	38,494
Stock compensation	622,789	568,165
Deferred rent		336,070
Lease Liability	479,940
Research and development carryforward	73,155	73,156
Total deferred tax assets	15,869,921	11,543,205
Deferred tax liabilities:
IPR&D assets	(2,373,304)	(2,557,085)
Right of Use Asset	(192,160)
Depreciation	(154,678)	(205,859)
Total deferred tax liabilities	(2,720,142)	(2,762,944)
Deferred tax assets, net	13,149,779	8,780,261
Valuation allowance	$ (13,149,779)	(8,838,761)
Total deferred tax liabilities net		$ (58,500)

Income Taxes - Additional Information (Detail)	12 Months Ended
Income Taxes - Additional Information (Detail)	Dec. 31, 2019 USD ($)
Income Taxes [Line Items]
Operating loss carryforwards not subject to expiration	$ 23,019,173
Testing period	3 years
Minimum [Member]
Income Taxes [Line Items]
Ownership percentage	50.00%
U.S. Federal [Member]
Income Taxes [Line Items]
Net operating loss carryforwards	$ 29,596,042
Operating Loss carryforwards, subject to expiration	$ 6,576,869
Operating loss carry forwards expiration period	20 years
Net operating loss carryforwards, expiration date	Jan. 01, 2021

Lease Obligations - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Leases [Abstract]
Non-cancellable lease maturity period	2022-12
Operating lease rent expense	$ 346,603	$ 632,658
Amortization of lease incentive obligation	164,090	$ 115,782
Cash paid for operating lease liabilities	$ 380,805

Lease Obligations - Summary of Supplemental other Information Related to Operating Leases Balance Sheet (Detail)	Dec. 31, 2019 USD ($)
Leases [Abstract]
Operating lease obligations	$ 1,744,128
Right of use asset	$ 698,321
Weighted-average remaining lease term	5 years 3 months 29 days
Weighted-average discount rate	8.00%

Lease Obligations - Summary of Maturities of Lease Liabilities (Detail)	Dec. 31, 2019 USD ($)
Leases [Abstract]
2020	$ 387,079
2021	393,542
2022	400,198
2023	407,054
2024	414,117
2025 and thereafter	138,831
Total lease payments	2,140,821
Less imputed interest	(396,693)
Total	$ 1,744,128

Commitments and Contingencies - Additional Information (Details) - Spitfire Pharma, Inc. [Member] - Sales Milestones [Member] $ in Millions	Jul. 12, 2019 USD ($)
Commitments And Contingencies [Line Items]
Future contingent payments	$ 80.0
License agreement term	10 years

Fair Value Measurement - Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis (Detail) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Short-term investments	$ 28,277,386
Fair Value, Measurements, Recurring [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Short-term investments	28,277,386
Contingent consideration	2,750,000
Warrant liability	10,000	$ 65,000
Fair Value, Measurements, Recurring [Member] \| Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Short-term investments	28,277,386
Fair Value, Measurements, Recurring [Member] \| Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Contingent consideration	2,750,000
Warrant liability	10,000	65,000
Fair Value, Measurements, Recurring [Member] \| Money Market Funds [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash equivalents	8,034,640	29,375,509
Fair Value, Measurements, Recurring [Member] \| Money Market Funds [Member] \| Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash equivalents	$ 8,034,640	$ 29,375,509

Fair Value Measurement - Schedule of Short Term Investments (Detail)	Dec. 31, 2019 USD ($)
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 28,257,379
Unrealized Gain	20,007
Market Value	28,277,386
United States Treasury Securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	3,394,579
Unrealized Gain	3,228
Market Value	3,397,807
Corporate Debt Securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	24,862,800
Unrealized Gain	16,779
Market Value	$ 24,879,579

Fair Value Measurement - Summary of Assumptions Used to Estimate Fair Value of Contingent Payments (Detail) - Level 3 [Member]	Dec. 31, 2019
Expected Volatility [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assumptions used to estimate fair value of contingent payments	95.3
Risk-free Interest Rate [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assumptions used to estimate fair value of contingent payments	1.6
Cost of Capital [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assumptions used to estimate fair value of contingent payments	30.0

Fair Value Measurement - Additional Information (Detail) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Fair Value Disclosures [Abstract]
Fair value transfers, Level 1 to Level 2 assets	$ 0	$ 0
Fair value transfers, Level 2 to Level 1 assets	0	0
Fair value transfers, Level 1 to Level 2 liabilities	0	0
Fair value transfers, Level 2 to Level 1 liabilities	$ 0	$ 0

Employee Benefit Plans - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Defined Contribution Pension And Other Postretirement Plans Disclosure [Abstract]
Discretionary plan contributions	$ 131,412	$ 139,042